| 1 | Real-World and Clinical Trial Validation of a Deep Learning Radiomic Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced Non-Small Cell Lung Cancer. (Sako C, Duan C, Maresca K, Kent S, Schmidt TG, Aerts HJWL, Parikh RB, Simon GR, Jordan P) JCO Clin Cancer Inform 2024 Dec;8:e2400133 |
| 1 | Understanding how CD19 expression levels impact the response to loncastuximab tesirine: a plain language summary. (Caimi PF, Hamadani M, Carlo-Stella C, Nickaeen M, Jordie E, Utsey K, Knab T, Zammarchi F, Cucchi D, Pantano S, Havenith K, Boni J) Future Oncol 2025 Feb;21(3):271-279 |
| 3 | Immunohistochemistry in the Differential Diagnosis of Triple Negative Breast Carcinoma and High-grade Serous Carcinoma: Old and New Markers. (Jain PV, Molina M, Moh M, Bishop E, Rader JS, Jorns JM) Appl Immunohistochem Mol Morphol 2024 Nov-Dec 01;32(10):456-461 |
| 1 | Characterization of driver mutations identifies gene signatures predictive of prognosis and treatment sensitivity in multiple myeloma. (Li JR, Parthasarathy AK, Kannappan AS, Arsang-Jang S, Dong J, Cheng C) Oncologist 2024 Nov 04;29(11):e1552-e1564 |
| 1 | Machine learning identifies prognostic subtypes of the tumor microenvironment of NSCLC. (Yu D, Kane MJ, Koay EJ, Wistuba II, Hobbs BP) Sci Rep 2024 Jul 01;14(1):15004 1 Citation |
| 1 | Advancing Precision Equity With Multicancer Detection Liquid Biopsies. (Semenkovich NP, Agarwal G, Chaudhuri AA) JAMA Oncol 2024 Aug 01;10(8):1023-1024 |
| 1 | Tumor biomechanical stiffness by magnetic resonance elastography predicts surgical outcomes and identifies biomarkers in vestibular schwannoma and meningioma. (Duhon BH, Thompson K, Fisher M, Kaul VF, Nguyen HT, Harris MS, Varadarajan V, Adunka OF, Prevedello DM, Kolipaka A, Ren Y) Sci Rep 2024 Jun 24;14(1):14561 2 Citations |
| 1 | MicroRNAs in extracellular vesicles: A potential role in cancer progression. (Parashar D, Mukherjee T, Gupta S, Kumar U, Das K) Cell Signal 2024 Sep;121:111263 8 Citations |
| 1 | Chordoma: Genetics and Contemporary Management. (Desai R, Pelargos PE, Dunn IF) Int J Mol Sci 2024 May 28;25(11) |
| 3 | Clinicopathologic Characteristics of a Single-institution Cohort of Ovarian Adult Granulosa Cell Tumors, With Biomarker and Therapeutic Implications Utilizing the Detection of Androgen, Estrogen, and Progesterone Hormone Receptor Expression by Immunohistochemistry. (Moh M, Puzyrenko A, Summey R, Rader JS, Herrera Cano GE, Gavina JV, Rui H, Sun Y, Hopp E) Int J Gynecol Pathol 2024 Sep 01;43(5):527-534 1 Citation |
| 1 | Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity. (Glitza IC, Seo YD, Spencer CN, Wortman JR, Burton EM, Alayli FA, Loo CP, Gautam S, Damania A, Densmore J, Fairchild J, Cabanski CR, Wong MC, Peterson CB, Weiner B, Hicks N, Aunins J, McChalicher C, Walsh E, Tetzlaff MT, Hamid O, Ott PA, Boland GM, Sullivan RJ, Grossmann KF, Ajami NJ, LaVallee T, Henn MR, Tawbi HA, Wargo JA) Cancer Discov 2024 Jul 01;14(7):1161-1175 13 Citations |
| 1 | Viewing the immune checkpoint VISTA: landscape and outcomes across cancers. (Nishizaki D, Kurzrock R, Miyashita H, Adashek JJ, Lee S, Nikanjam M, Eskander RN, Patel H, Botta GP, Nesline MK, Pabla S, Conroy JM, DePietro P, Sicklick JK, Kato S) ESMO Open 2024 Apr;9(4):102942 5 Citations |
| 1 | Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design. (Fountzilas E, Tsimberidou AM, Hiep Vo H, Kurzrock R) Cancer Treat Rev 2024 Apr;125:102703 3 Citations |
| 1 | Pan-cancer Genomic Analysis of AXL Mutations Reveals a Novel, Recurrent, Functionally Activating AXL W451C Alteration Specific to Myxofibrosarcoma. (Williams EA, Vegas I, El-Senduny FF, Zhang J, Mata DA, Hiemenz MC, Hughes SR, Sa BC, Kraft GP, Gorbatov N, Foley-Peres K, Sanchez EZ, Milikowski C, Williams KJ, Ross JS, Kurzrock R, Montgomery EA, Lombard DB, Kumar S) Am J Surg Pathol 2024 Jun 01;48(6):699-707 2 Citations |
| 1 | Preoperative CA 19-9 Predicts Disease Progression in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Analysis from the US HIPEC Collaborative. (Fackche NT, Schmocker RK, Nudotor R, Kubi B, Cloyd JM, Grotz TE, Fournier KF, Dineen SP, Veerapong J, Baumgartner JM, Clarke CN, Patel SH, Wilson GC, Lambert LA, Pokrzywa C, Abbott DE, Lee B, Staley CA, Zaidi MY, Johnston FM, Greer JB) Ann Surg Oncol 2024 May;31(5):3314-3324 1 Citation |
| 7 | Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma. (George B, Kudryashova O, Kravets A, Thalji S, Malarkannan S, Kurzrock R, Chernyavskaya E, Gusakova M, Kravchenko D, Tychinin D, Savin E, Alekseeva L, Butusova A, Bagaev A, Shin N, Brown JH, Sethi I, Wang D, Taylor B, McFall T, Kamgar M, Hall WA, Erickson B, Christians KK, Evans DB, Tsai S) Gastroenterology 2024 May;166(5):859-871.e3 8 Citations |
| 1 | Imaging and Biomarker Surveillance for Head and Neck Squamous Cell Carcinoma: A Systematic Review and American Radium Society Appropriate Use Criteria Statement. (Hanna GJ, Chang SS, Siddiqui F, Bain PA, Takiar V, Ward MC, Shukla ME, Hu KS, Robbins J, Witek ME, Bakst R, Chandra RA, Galloway T, Margalit DN) Int J Radiat Oncol Biol Phys 2024 Jul 01;119(3):786-802 |
| 1 | Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity. (Lim J, Kurzrock R, Nishizaki D, Miyashita H, Adashek JJ, Lee S, Pabla S, Nesline M, Conroy JM, DePietro P, Lippman SM, Kato S) Cancer Med 2024 Jan;13(1):e6844 3 Citations |
| 2 | Methylation signatures as biomarkers for non-invasive early detection of breast cancer: A systematic review of the literature. (Gonzalez T, Nie Q, Chaudhary LN, Basel D, Reddi HV) Cancer Genet 2024 Apr;282-283:1-8 5 Citations |
| 1 | Considering molecular alterations as pan-cancer tissue-agnostic targets. (Adashek JJ, Kato S, Sicklick JK, Lippman SM, Kurzrock R) Nat Cancer 2023 Dec;4(12):1622-1626 5 Citations |
| 1 | Sarcomas Harboring EWSR1::PATZ1 Fusions: A Clinicopathologic Study of 17 Cases. (Dehner CA, Torres-Mora J, Gupta S, Kipp BR, Halling KC, Chen S, Warmke LM, Michal M, Alani A, Yu W, Kovacs K, Obeidin F, Iwenofu OH, Satturwar S, Meis JM, Folpe AL) Mod Pathol 2024 Feb;37(2):100400 7 Citations |
| 1 | Evaluation of Diagnostic Significance of Salivary miRNA-184 and miRNA-21 in Oral Squamous Cell Carcinoma and Oral Potentially Malignant Disorders. (Garg A, Urs AB, Koner BC, Augustine J, Guru SA) Head Neck Pathol 2023 Dec;17(4):961-968 3 Citations |
| 1 | Diagnostic Performance of Magnetic Resonance Imaging for Pediatric Ovarian Neoplasms: A Multi-Institutional Review. (Bergus KC, Knaus ME, Onwuka AJ, Afrazi A, Breech L, Corkum KS, Dillon PA, Ehrlich PF, Fallat ME, Fraser JD, Gadepalli SK, Grabowski JE, Hertweck SP, Kabre R, Lal DR, Landman MP, Leys CM, Mak GZ, Markel TA, Merchant N, Overman RE, Rademacher BL, Raiji MT, Rymeski B, Sato TT, Wright T, Aldrink JH, Hewitt GD, Minneci PC, Deans KJ, Midwest Pediatric Surgery Consortium) J Pediatr Adolesc Gynecol 2024 Apr;37(2):192-197 1 Citation |
| 1 | Revolutionizing cancer drug development: Harnessing the potential of basket trials. (Subbiah V, Burris HA 3rd, Kurzrock R) Cancer 2024 Jan;130(2):186-200 11 Citations |
| 1 | Tumour mutational burden and survival with molecularly matched therapy. (de Bortoli T, Benary M, Horak P, Lamping M, Stintzing S, Tinhofer I, Leyvraz S, Schäfer R, Klauschen F, Keller U, Stenzinger A, Fröhling S, Kurzrock R, Keilholz U, Rieke DT, Jelas I) Eur J Cancer 2023 Sep;190:112925 2 Citations |
| 1 | Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology. (Earland N, Chen K, Semenkovich NP, Chauhan PS, Zevallos JP, Chaudhuri AA) Semin Radiat Oncol 2023 Jul;33(3):262-278 10 Citations |
| 1 | Blood-Based Biomarkers in the Diagnosis and Risk Stratification of Pancreatic Cysts. (Peller MT, Das KK) Gastrointest Endosc Clin N Am 2023 Jul;33(3):559-581 |
| 2 | Resected cytokeratin-negative small cell lung carcinoma. (Jain PV, Thompson J, Sheinin Y) BMJ Case Rep 2023 Apr 03;16(4) |
| 1 | Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry. (Robbins CJ, Fernandez AI, Han G, Wong S, Harigopal M, Podoll M, Singh K, Ly A, Kuba MG, Wen H, Sanders MA, Brock J, Wei S, Fadare O, Hanley K, Jorns J, Snir OL, Yoon E, Rabe K, Soong TR, Reisenbichler ES, Rimm DL) Mod Pathol 2023 Jan;36(1):100032 37 Citations |
| 1 | Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real-world precision-medicine population. (Rosenberg S, Ben Cohen G, Kato S, Okamura R, Lippman SM, Kurzrock R) Mol Oncol 2023 Sep;17(9):1844-1856 1 Citation |
| 2 | Lipofibromatosis-like neural tumors: Report of a case and review of 73 reported cases. (Ulschmid CM, Singam V, Segura A, Gourlay DM, Chiu YE) Pediatr Dermatol 2023;40(4):664-668 2 Citations |
| 1 | A simplified molecular method to detect high-risk HPV using the Aptima HPV assay on head and neck FNA smears. (Gormley JP, Selvaggi SM, Rehrauer WM, Kucher ET) Cancer Cytopathol 2023 Mar;131(3):171-178 2 Citations |
| 2 | Contemporary evaluation of estrogen receptor and progesterone receptor expression in breast cancer-associated stroma. (Moreno GA, Molina MI, Eastwood D, Auer PL, Jorns JM) Breast Cancer Res Treat 2022 Dec;196(3):453-461 1 Citation |
| 1 | High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting. (Joshi RS, Boichard A, Adashek JJ, Kurzrock R) Cancer Biol Ther 2022 Dec 31;23(1):1-6 3 Citations |
| 1 | A rare case of primary cutaneous malignant perivascular epithelioid cell tumor and review of the literature. (Cornell G, Jiang B, Ghaferi J) J Cutan Pathol 2023 Apr;50(4):301-305 3 Citations |
| 1 | Multi-omic analysis in carcinoma of unknown primary (CUP): therapeutic impact of knowing the unknown. (Kato S, Gumas S, Adashek JJ, Okamura R, Lee S, Sicklick JK, Kurzrock R) Mol Oncol 2024 Apr;18(4):956-968 7 Citations |
| 1 | Circular RNAs as novel biomarkers in triple-negative breast cancer: a systematic review. (Foruzandeh Z, Dorabadi DG, Sadeghi F, Zeinali-Sehrig F, Zaefizadeh M, Rahmati Y, Alivand MR) Mol Biol Rep 2022 Oct;49(10):9825-9840 4 Citations |
| 1 | Cutaneous perivascular epithelioid cell tumor (PEComa): case report and world literature review of clinical and molecular characteristics. (Cohen PR, Kato SM, Erickson CP, Calame A, Kurzrock R) Dermatol Online J 2022 Jan 15;28(1) 8 Citations |
| 1 | New Challenges in the Differential Diagnosis of High-Grade Triple-Negative Breast Cancer and Serous Carcinoma. (Puzyrenko A, Cortina CS, Jorns JM) Int J Surg Pathol 2022 Oct;30(7):728-733 1 Citation |
| 1 | Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials. (Szeto CW, Kurzrock R, Kato S, Goloubev A, Veerapaneni S, Preble A, Reddy SK, Adashek JJ) ESMO Open 2022 Feb;7(1):100396 11 Citations |
| 1 | Multi-Institutional Review of the Preoperative Diagnostic Accuracy for Pediatric Ovarian Mature Cystic Teratomas. (Knaus ME, Onwuka AJ, Afrazi A, Breech L, Corkum KS, Dillon PA, Ehrlich PF, Fallat ME, Fraser JD, Gadepalli SK, Grabowski JE, Hertweck SP, Kabre R, Lal DR, Landman MP, Lawrence AE, Leys CM, Mak GZ, Markel TA, Merchan N, Overman RE, Rademacher BL, Raiji MT, Rymeski B, Sato TT, Scannel M, Schikler AG, Sujka JA, Wright T, Aldrink JH, Hewitt GD, Minneci PC, Deans KJ, Midwest Pediatric Surgery Consortium) J Pediatr Adolesc Gynecol 2022 Aug;35(4):478-485 1 Citation |
| 1 | NF2-mutated Renal Carcinomas Have Common Morphologic Features Which Overlap With Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma: A Comprehensive Study of 14 Cases. (Paintal A, Tjota MY, Wang P, Fitzpatrick C, Wanjari P, Stadler WM, Gallan AJ, Segal J, Antic T) Am J Surg Pathol 2022 May 01;46(5):617-627 18 Citations |
| 1 | Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. (Das A, Sudhaman S, Morgenstern D, Coblentz A, Chung J, Stone SC, Alsafwani N, Liu ZA, Karsaneh OAA, Soleimani S, Ladany H, Chen D, Zatzman M, Cabric V, Nobre L, Bianchi V, Edwards M, Sambira Nahum LC, Ercan AB, Nabbi A, Constantini S, Dvir R, Yalon-Oren M, Campino GA, Caspi S, Larouche V, Reddy A, Osborn M, Mason G, Lindhorst S, Bronsema A, Magimairajan V, Opocher E, De Mola RL, Sabel M, Frojd C, Sumerauer D, Samuel D, Cole K, Chiaravalli S, Massimino M, Tomboc P, Ziegler DS, George B, Van Damme A, Hijiya N, Gass D, McGee RB, Mordechai O, Bowers DC, Laetsch TW, Lossos A, Blumenthal DT, Sarosiek T, Yen LY, Knipstein J, Bendel A, Hoffman LM, Luna-Fineman S, Zimmermann S, Scheers I, Nichols KE, Zapotocky M, Hansford JR, Maris JM, Dirks P, Taylor MD, Kulkarni AV, Shroff M, Tsang DS, Villani A, Xu W, Aronson M, Durno C, Shlien A, Malkin D, Getz G, Maruvka YE, Ohashi PS, Hawkins C, Pugh TJ, Bouffet E, Tabori U) Nat Med 2022 Jan;28(1):125-135 81 Citations |
| 1 | Common variants in breast cancer risk loci predispose to distinct tumor subtypes. (Ahearn TU, Zhang H, Michailidou K, Milne RL, Bolla MK, Dennis J, Dunning AM, Lush M, Wang Q, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Auer PL, Augustinsson A, Baten A, Becher H, Behrens S, Benitez J, Bermisheva M, Blomqvist C, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Brenner H, Brooks-Wilson A, Brüning T, Burwinkel B, Buys SS, Canzian F, Castelao JE, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Clarke CL, NBCS Collaborators, Collée JM, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dwek M, Eccles DM, Evans DG, Fasching PA, Figueroa J, Floris G, Gago-Dominguez M, Gapstur SM, García-Sáenz JA, Gaudet MM, Giles GG, Goldberg MS, González-Neira A, Alnæs GIG, Grip M, Guénel P, Haiman CA, Hall P, Hamann U, Harkness EF, Heemskerk-Gerritsen BAM, Holleczek B, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, ABCTB Investigators, kConFab/AOCS Investigators, Jakimovska M, Jakubowska A, John EM, Jones ME, Jung A, Kaaks R, Kauppila S, Keeman R, Khusnutdinova E, Kitahara CM, Ko YD, Koutros S, Kristensen VN, Krüger U, Kubelka-Sabit K, Kurian AW, Kyriacou K, Lambrechts D, Lee DG, Lindblom A, Linet M, Lissowska J, Llaneza A, Lo WY, MacInnis RJ, Mannermaa A, Manoochehri M, Margolin S, Martinez ME, McLean C, Meindl A, Menon U, Nevanlinna H, Newman WG, Nodora J, Offit K, Olsson H, Orr N, Park-Simon TW, Patel AV, Peto J, Pita G, Plaseska-Karanfilska D, Prentice R, Punie K, Pylkäs K, Radice P, Rennert G, Romero A, Rüdiger T, Saloustros E, Sampson S, Sandler DP, Sawyer EJ, Schmutzler RK, Schoemaker MJ, Schöttker B, Sherman ME, Shu XO, Smichkoska S, Southey MC, Spinelli JJ, Swerdlow AJ, Tamimi RM, Tapper WJ, Taylor JA, Teras LR, Terry MB, Torres D, Troester MA, Vachon CM, van Deurzen CHM, van Veen EM, Wagner P, Weinberg CR, Wendt C, Wesseling J, Winqvist R, Wolk A, Yang XR, Zheng W, Couch FJ, Simard J, Kraft P, Easton DF, Pharoah PDP, Schmidt MK, García-Closas M, Chatterjee N) Breast Cancer Res 2022 Jan 04;24(1):2 17 Citations |
| 1 | Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach. (McFall T, Stites EC) Cell Rep 2021 Dec 14;37(11):110096 11 Citations |
| 1 | Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. (Friedman CF, Hainsworth JD, Kurzrock R, Spigel DR, Burris HA, Sweeney CJ, Meric-Bernstam F, Wang Y, Levy J, Grindheim J, Shames DS, Schulze K, Patel A, Swanton C) Cancer Discov 2022 Mar 01;12(3):654-669 58 Citations |
| 1 | A 39-Year-Old Woman With Synchronous Endobronchial and Adrenal Tumors. (Singh H, Jani CT, Abdalla M, Puzyrenko A, Kurman JS, Benn BS) Chest 2021 Dec;160(6):e629-e632 |
| 1 | PLEKHA7 signaling is necessary for the growth of mutant KRAS driven colorectal cancer. (Jeung HC, Puentes R, Aleshin A, Indarte M, Correa RG, Bankston LA, Layng FIAL, Ahmed Z, Wistuba I, Yao Y, Duenas DG, Zhang S, Meuillet EJ, Marassi F, Liddington RC, Kirkpatrick L, Powis G) Exp Cell Res 2021 Dec 15;409(2):112930 1 Citation |
| 1 | Integrative analysis of DNA methylation and gene expression profiles to identify biomarkers of glioblastoma. (Alivand MR, Najafi S, Esmaeili S, Rahmanpour D, Zhaleh H, Rahmati Y) Cancer Genet 2021 Nov;258-259:135-150 12 Citations |
| 1 | Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast. (Yadav S, Hu C, Nathanson KL, Weitzel JN, Goldgar DE, Kraft P, Gnanaolivu RD, Na J, Huang H, Boddicker NJ, Larson N, Gao C, Yao S, Weinberg C, Vachon CM, Trentham-Dietz A, Taylor JA, Sandler DR, Patel A, Palmer JR, Olson JE, Neuhausen S, Martinez E, Lindstrom S, Lacey JV, Kurian AW, John EM, Haiman C, Bernstein L, Auer PW, Anton-Culver H, Ambrosone CB, Karam R, Chao E, Yussuf A, Pesaran T, Dolinsky JS, Hart SN, LaDuca H, Polley EC, Domchek SM, Couch FJ) J Clin Oncol 2021 Dec 10;39(35):3918-3926 32 Citations |
| 1 | CircRNAs as potent biomarkers in ovarian cancer: a systematic scoping review. (Foruzandeh Z, Zeinali-Sehrig F, Nejati K, Rahmanpour D, Pashazadeh F, Seif F, Alivand MR) Cell Mol Biol Lett 2021 Sep 23;26(1):41 20 Citations |
| 1 | Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible. (Jensen TJ, Goodman AM, Ellison CK, Holden KA, Kato S, Kim L, Daniels GA, Fitzgerald K, McCarthy E, Nakashe P, Mazloom AR, Almasri E, McLennan G, Grosu DS, Eisenberg M, Kurzrock R) Mol Cancer Ther 2021 Nov;20(11):2274-2279 6 Citations |
| 6 | Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth. (Geethadevi A, Nair A, Parashar D, Ku Z, Xiong W, Deng H, Li Y, George J, McAllister DM, Sun Y, Kadamberi IP, Gupta P, Dwinell MB, Bradley WH, Rader JS, Rui H, Schwabe RF, Zhang N, Pradeep S, An Z, Chaluvally-Raghavan P) Cancer Res 2021 Oct 15;81(20):5336-5352 37 Citations |
| 1 | SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. (Botta GP, Kato S, Patel H, Fanta P, Lee S, Okamura R, Kurzrock R) JCI Insight 2021 Sep 22;6(18) 43 Citations |
| 1 | Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. (Boddicker NJ, Hu C, Weitzel JN, Kraft P, Nathanson KL, Goldgar DE, Na J, Huang H, Gnanaolivu RD, Larson N, Yussuf A, Yao S, Vachon CM, Trentham-Dietz A, Teras L, Taylor JA, Scott CE, Sandler DP, Pesaran T, Patel AV, Palmer JR, Ong IM, Olson JE, O'Brien K, Neuhausen S, Martinez E, Ma H, Lindstrom S, Le Marchand L, Kooperberg C, Karam R, Hunter DJ, Hodge JM, Haiman C, Gaudet MM, Gao C, LaDuca H, Lacey JV, Dolinsky JS, Chao E, Carter BD, Burnside ES, Bertrand KA, Bernstein L, Auer PW, Ambrosone C, Yadav S, Hart SN, Polley EC, Domchek SM, Couch FJ) J Clin Oncol 2021 Nov 01;39(31):3430-3440 24 Citations |
| 3 | Nuclear PFKP promotes CXCR4-dependent infiltration by T cell acute lymphoblastic leukemia. (Gao X, Qin S, Wu Y, Chu C, Jiang B, Johnson RH, Kuang D, Zhang J, Wang X, Mehta A, Tew KD, Leone GW, Yu XZ, Wang H) J Clin Invest 2021 Aug 16;131(16) 29 Citations |
| 1 | Immunophenotype-associated gene signature in ductal breast tumors varies by receptor subtype, but the expression of individual signature genes remains consistent. (Behring M, Ye Y, Elkholy A, Bajpai P, Agarwal S, Kim HG, Ojesina AI, Wiener HW, Manne U, Shrestha S, Vazquez AI) Cancer Med 2021 Aug;10(16):5712-5720 4 Citations |
| 1 | Expression patterns for Bcl-2, EMA, β-catenin, E-cadherin, PAX8, and MIB1 in thymomas. (Suster D, Miller JA, Pihan G, Mackinnon AC, Suster S) Mod Pathol 2021 Oct;34(10):1831-1838 7 Citations |
| 1 | A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. (Fujii T, Masuda H, Cheng YC, Yang F, Sahin AA, Naoi Y, Matsunaga Y, Raghavendra A, Sinha AK, Fernandez JRE, James A, Yamagishi K, Matsushima T, Schuetz R, Tripathy D, Tada S, Jackson RS, Noguchi S, Nakamura S, Acoba JD, Ueno NT) Breast Cancer Res Treat 2021 Sep;189(2):455-461 7 Citations |
| 1 | LPCAT1-TERT fusions are uniquely recurrent in epithelioid trophoblastic tumors and positively regulate cell growth. (Oliver GR, Marcano-Bonilla S, Quist J, Tolosa EJ, Iguchi E, Swanson AA, Hoppman NL, Schwab T, Sigafoos A, Prodduturi N, Voss JS, Knight SM, Zhang J, Fadra N, Urrutia R, Zimmerman M, Egan JB, Bilyeu AG, Jen J, Veras E, Al-Safi R, Block M, Kerr S, Fernandez-Zapico ME, Schoolmeester JK, Klee EW) PLoS One 2021;16(5):e0250518 8 Citations |
| 1 | HER-2/neu-positive breast cancer neoadjuvant chemotherapy response after implementation of 2018 ASCO/CAP focused update. (Wang L, Asirvatham JR, Ma Y, Reisenbichler ES, Jorns JM) Breast J 2021 Aug;27(8):631-637 6 Citations |
| 1 | MicroRNA-22 in female malignancies: Focusing on breast, cervical, and ovarian cancers. (Nejati K, Alivand M, Arabzadeh A) Pathol Res Pract 2021 Jul;223:153452 23 Citations |
| 1 | BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort. (Vassilakopoulou M, Won M, Curran WJ, Souhami L, Prados MD, Langer CJ, Rimm DL, Hanna JA, Neumeister VM, Melian E, Diaz AZ, Atkins JN, Komarnicky LT, Schultz CJ, Howard SP, Zhang P, Dicker AP, Knisely JPS) Oncology 2021;99(9):580-588 5 Citations |
| 1 | Synthetic lethality-mediated precision oncology via the tumor transcriptome. (Lee JS, Nair NU, Dinstag G, Chapman L, Chung Y, Wang K, Sinha S, Cha H, Kim D, Schperberg AV, Srinivasan A, Lazar V, Rubin E, Hwang S, Berger R, Beker T, Ronai Z, Hannenhalli S, Gilbert MR, Kurzrock R, Lee SH, Aldape K, Ruppin E) Cell 2021 Apr 29;184(9):2487-2502.e13 72 Citations |
| 1 | Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker. (Fountzilas E, Kurzrock R, Vo HH, Tsimberidou AM) J Natl Cancer Inst 2021 Nov 29;113(12):1634-1647 29 Citations |
| 1 | MiR-330-3p and miR-485-5p as biomarkers for glioblastoma: An integrated bioinformatics and experimental study. (Rahmati Y, Alivand M, Mollanoori H) Comput Biol Chem 2021 Jun;92:107458 7 Citations |
| 1 | A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease. (Halle MK, Sødal M, Forsse D, Engerud H, Woie K, Lura NG, Wagner-Larsen KS, Trovik J, Bertelsen BI, Haldorsen IS, Ojesina AI, Krakstad C) Br J Cancer 2021 May;124(10):1690-1698 21 Citations |
| 1 | The Utility of Preoperative Tumor Markers in Peritoneal Carcinomatosis from Primary Appendiceal Adenocarcinoma: an Analysis from the US HIPEC Collaborative. (Fackche N, Schmocker RK, Kubi B, Cloyd JM, Ahmed A, Grotz T, Leiting J, Fournier K, Lee AJ, Powers B, Dineen S, Veerapong J, Baumgartner JM, Clarke C, Gamblin TC, Patel SH, Dhar V, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Lafaro K, Lee B, Zaidi MY, Maithel SK, Johnston FM, Greer JB) J Gastrointest Surg 2021 Nov;25(11):2908-2919 7 Citations |
| 1 | Reliability of Serum Tumor Marker Measurement to Diagnose Recurrence in Patients with Clinical Stage I Nonseminomatous Germ Cell Tumors Undergoing Active Surveillance: A Systematic Review. (Chakiryan NH, Dahmen A, Cucchiara V, Briganti A, Montorsi F, Salonia A, Spiess PE, Necchi A) J Urol 2021 Jun;205(6):1569-1576 7 Citations |
| 1 | Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. (Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Apsel Winger B, Cooper TM, Pauly M, Maloney KW, Burke MJ, Brown PA, Gossai N, McNeer JL, Shukla NN, Cole PD, Kahn JM, Chen J, Barth MJ, Magee JA, Gennarini L, Adhav AA, Clinton CM, Ocasio-Martinez N, Gotti G, Li Y, Lin S, Imamovic A, Tognon CE, Patel T, Faust HL, Contreras CF, Cremer A, Cortopassi WA, Garrido Ruiz D, Jacobson MP, Dharia NV, Su A, Robichaud AL, Saur Conway A, Tarlock K, Stieglitz E, Place AE, Puissant A, Hunger SP, Kim AS, Lindeman NI, Gore L, Janeway KA, Silverman LB, Tyner JW, Harris MH, Loh ML, Stegmaier K) Cancer Discov 2021 Jun;11(6):1424-1439 27 Citations |
| 1 | Distal Tubular Hyperplasia: A Proposal for a Unique Form of Renal Tubular Proliferation Distinct From Papillary Adenoma. (Williamson SR, Al-Obaidy KI, Cheng L, Smith SC, Cox RM, McKenney JK, Gokden N, Phillips CL, Giannico GA, Gallan AJ, Przybycin CG, Grignon DJ) Am J Surg Pathol 2021 Apr 01;45(4):516-522 3 Citations |
| 1 | Cytokeratin 7, GATA3, and SOX-10 is a Comprehensive Panel in Diagnosing Triple Negative Breast Cancer Brain Metastases. (Statz E, Jorns JM) Int J Surg Pathol 2021 Aug;29(5):470-474 11 Citations |
| 1 | Cancer of Unknown Primary in the Molecular Era. (Kato S, Alsafar A, Walavalkar V, Hainsworth J, Kurzrock R) Trends Cancer 2021 May;7(5):465-477 47 Citations |
| 1 | Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics. (Kato S, Adashek JJ, Shaya J, Okamura R, Jimenez RE, Lee S, Sicklick JK, Kurzrock R) Clin Cancer Res 2021 May 15;27(10):2792-2797 32 Citations |
| 2 | NOGOB receptor-mediated RAS signaling pathway is a target for suppressing proliferating hemangioma. (Hu W, Liu Z, Salato V, North PE, Bischoff J, Kumar SN, Fang Z, Rajan S, Hussain MM, Miao QR) JCI Insight 2021 Feb 08;6(3) 11 Citations |
| 1 | New Prognostic Indicators in Pediatric Adrenal Tumors: Neuroblastoma and Adrenal Cortical Tumors, Can We Predict When These Will Behave Badly? (Jarzembowski JA) Surg Pathol Clin 2020 Dec;13(4):625-641 5 Citations |
| 1 | Wilms Tumor: Challenges and Newcomers in Prognosis. (Parsons LN) Surg Pathol Clin 2020 Dec;13(4):683-693 6 Citations |
| 1 | The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. (Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R) Cancer Cell 2021 Feb 08;39(2):154-173 671 Citations |
| 3 | Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. (Dhakal B, D'Souza A, Callander N, Chhabra S, Fraser R, Davila O, Anderson K, Assal A, Badawy SM, Berdeja J, Cerny J, Comenzo R, Chakraborty R, Peter Gale R, Kamble R, Kharfan-Dabaja MA, Krem M, Ganguly S, Janakiram M, Kansagra A, Munker R, Murthy H, Patel S, Kumar S, Shah N, Qazilbash M, Hari P) Br J Haematol 2020 Nov;191(3):442-452 9 Citations |
| 1 | From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. (Adashek JJ, Subbiah V, Kurzrock R) Trends Cancer 2021 Jan;7(1):15-28 75 Citations |
| 1 | Survival Implications of the Relationship between Tissue versus Circulating Tumor DNA TP53 Mutations-A Perspective from a Real-World Precision Medicine Cohort. (Rosenberg S, Okamura R, Kato S, Soussi T, Kurzrock R) Mol Cancer Ther 2020 Dec;19(12):2612-2620 8 Citations |
| 1 | Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies. (Han L, Gallan AJ, Steinberg GD, Sweis RF, Paner GP) Hum Pathol 2020 Dec;106:54-61 6 Citations |
| 1 | Transcriptomics and solid tumors: The next frontier in precision cancer medicine. (Tsimberidou AM, Fountzilas E, Bleris L, Kurzrock R) Semin Cancer Biol 2022 Sep;84:50-59 52 Citations |
| 1 | Tumor mutational burden is not predictive of cytotoxic chemotherapy response. (Nikanjam M, Riviere P, Goodman A, Barkauskas DA, Frampton G, Kurzrock R) Oncoimmunology 2020 Jun 24;9(1):1781997 12 Citations |
| 1 | Sex-Specific Genetic Associations for Barrett's Esophagus and Esophageal Adenocarcinoma. (Dong J, Maj C, Tsavachidis S, Ostrom QT, Gharahkhani P, Anderson LA, Wu AH, Ye W, Bernstein L, Borisov O, Schröder J, Chow WH, Gammon MD, Liu G, Caldas C, Pharoah PD, Risch HA, May A, Gerges C, Anders M, Venerito M, Schmidt T, Izbicki JR, Hölscher AH, Schumacher B, Vashist Y, Neuhaus H, Rösch T, Knapp M, Krawitz P, Böhmer A, Iyer PG, Reid BJ, Lagergren J, Shaheen NJ, Corley DA, Gockel I, Fitzgerald RC, Stomach and Oesophageal Cancer Study (SOCS) consortium, Cook MB, Whiteman DC, Vaughan TL, Schumacher J, Thrift AP) Gastroenterology 2020 Dec;159(6):2065-2076.e1 18 Citations |
| 3 | Utility of PD-L1 testing on non-small cell lung cancer cytology specimens: An institutional experience with interobserver variability analysis. (Kravtsov O, Hartley CP, Sheinin Y, Hunt BC, Felix JC, Giorgadze T) Ann Diagn Pathol 2020 Oct;48:151602 4 Citations |
| 1 | Chondroblastoma Expresses RANKL by RNA In Situ Hybridization and May Respond to Denosumab Therapy. (Suster DI, Kurzawa P, Neyaz A, Jarzembowski JA, Lozano-Calderon S, Raskin K, Schwab J, Choy E, Chebib I, Deshpande V) Am J Surg Pathol 2020 Dec;44(12):1581-1590 11 Citations |
| 2 | Discovery and validation of surface N-glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets. (Oldham RAA, Faber ML, Keppel TR, Buchberger AR, Waas M, Hari P, Gundry RL, Medin JA) J Immunother Cancer 2020 Aug;8(2) 14 Citations |
| 1 | Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases. (Baumgartner JM, Riviere P, Lanman RB, Kelly KJ, Veerapong J, Lowy AM, Kurzrock R) Ann Surg Oncol 2020 Sep;27(9):3259-3267 20 Citations |
| 1 | Circulating MicroRNAs as Potential Biomarkers in Glioma: A Mini-Review. (Choppavarapu L, Kandi SM) Endocr Metab Immune Disord Drug Targets 2021;21(2):195-202 3 Citations |
| 1 | Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials. (Schperberg AV, Boichard A, Tsigelny IF, Richard SB, Kurzrock R) Int J Cancer 2020 Nov 01;147(9):2537-2549 13 Citations |
| 3 | High neutrophil-lymphocyte ratio is not independently associated with worse survival or recurrence in patients with extremity soft tissue sarcoma. (Strong EA, Park SH, Ethun CG, Chow B, King D, Bedi M, Charlson J, Mogal H, Tsai S, Christians K, Tran TB, Poultsides G, Grignol V, Howard JH, Tseng J, Roggin KK, Chouliaras K, Votanopoulos K, Cullinan D, Fields RC, Gamblin TC, Cardona K, Clarke CN) Surgery 2020 Oct;168(4):760-767 5 Citations |
| 1 | Diagnostic utility of high-risk human papillomavirus mRNA in situ hybridisation in squamous cell carcinoma of unknown primary in the head and neck and implementing American Society of Clinical Oncology guideline recommendations. (Daneshpajouhnejad P, Miller JA, Maleki Z) Cytopathology 2020 Nov;31(6):547-554 6 Citations |
| 1 | Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing. (Boichard A, Wagner MJ, Kurzrock R) Genome Med 2020 Jul 09;12(1):61 35 Citations |
| 1 | Identification of Let-7f-5p as a novel biomarker of recurrence in non-muscle invasive bladder cancer. (Shee K, Seigne JD, Karagas MR, Marsit CJ, Hinds JW, Schned AR, Pettus JR, Armstrong DA, Miller TW, Andrew AS) Cancer Biomark 2020;29(1):101-110 11 Citations |
| 1 | A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer. (Oza AM, Estevez-Diz M, Grischke EM, Hall M, Marmé F, Provencher D, Uyar D, Weberpals JI, Wenham RM, Laing N, Tracy M, Freshwater T, Lee MA, Liu J, Qiu J, Rose S, Rubin EH, Moore K) Clin Cancer Res 2020 Sep 15;26(18):4767-4776 77 Citations |
| 1 | Prognostic factors of biochemical remission after transsphenoidal surgery for acromegaly: a structured review. (Agrawal N, Ioachimescu AG) Pituitary 2020 Oct;23(5):582-594 45 Citations |
| 1 | Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer. (Chamberlin MD, Wells JD, Shee K, Bean JR, Marotti JD, Wells WA, Trask HW, Kolling FW, Bhatt A, Kaufman PA, Schwartz GN, Gemery JM, McNulty NJ, Tsapakos MJ, Barth RJ, Arrick BA, Gui J, Miller TW) Breast Cancer Res Treat 2020 Aug;182(3):665-677 1 Citation |
| 1 | A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients. (Saha G, Singh R, Mandal A, Das S, Chattopadhyay E, Panja P, Roy P, DeSarkar N, Gulati S, Ghatak S, Ghosh S, Banerjee S, Roy B, Ghosh S, Chaudhuri D, Arora N, Biswas NK, Sikdar N) Mol Med 2020 Jun 17;26(1):59 15 Citations |
| 1 | Epigenomics-based identification of oestrogen-regulated long noncoding RNAs in ER+ breast cancer. (Zhang Z, Yu W, Tang D, Zhou Y, Bi M, Wang H, Zheng Y, Chen M, Li L, Xu X, Zhang W, Tao H, Jin VX, Liu Z, Chen L) RNA Biol 2020 Nov;17(11):1590-1602 10 Citations |
| 1 | CD105 is a prognostic marker and valid endothelial target for microbubble platforms in cholangiocarcinoma. (Nair A, Ingram N, Verghese ET, Wijetunga I, Markham AF, Wyatt J, Prasad KR, Coletta PL) Cell Oncol (Dordr) 2020 Oct;43(5):835-845 11 Citations |
| 1 | Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress. (Nyquist MD, Corella A, Coleman I, De Sarkar N, Kaipainen A, Ha G, Gulati R, Ang L, Chatterjee P, Lucas J, Pritchard C, Risbridger G, Isaacs J, Montgomery B, Morrissey C, Corey E, Nelson PS) Cell Rep 2020 May 26;31(8):107669 170 Citations |
| 1 | Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma. (Kandimalla R, Shimura T, Mallik S, Sonohara F, Tsai S, Evans DB, Kim SC, Baba H, Kodera Y, Von Hoff D, Chen X, Goel A) Ann Surg 2022 Jan 01;275(1):e229-e237 17 Citations |
| 1 | Review of precision cancer medicine: Evolution of the treatment paradigm. (Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R) Cancer Treat Rev 2020 Jun;86:102019 431 Citations |
| 1 | Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. (Kato S, Okamura R, Kumaki Y, Ikeda S, Nikanjam M, Eskander R, Goodman A, Lee S, Glenn ST, Dressman D, Papanicolau-Sengos A, Lenzo FL, Morrison C, Kurzrock R) Oncoimmunology 2020;9(1):1708065 49 Citations |
| 1 | ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. (Okamura R, Kato S, Lee S, Jimenez RE, Sicklick JK, Kurzrock R) J Immunother Cancer 2020 Feb;8(1) 131 Citations |
| 1 | The paradox of cancer genes in non-malignant conditions: implications for precision medicine. (Adashek JJ, Kato S, Lippman SM, Kurzrock R) Genome Med 2020 Feb 17;12(1):16 33 Citations |
| 2 | Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis. (Carlevaro-Fita J, Lanzós A, Feuerbach L, Hong C, Mas-Ponte D, Pedersen JS, PCAWG Drivers and Functional Interpretation Group, Johnson R, PCAWG Consortium) Commun Biol 2020 Feb 05;3(1):56 151 Citations |
| 5 | Improving Outcomes of Acute Promyelocytic Leukemia in the Current Era: Analysis of the SEER Database. (Guru Murthy GS, Szabo A, Michaelis L, Carlson KS, Runaas L, Abedin S, Atallah E) J Natl Compr Canc Netw 2020 Feb;18(2):169-175 27 Citations |
| 1 | Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer. (Huang KW, Hsu FF, Qiu JT, Chern GJ, Lee YA, Chang CC, Huang YT, Sung YC, Chiang CC, Huang RL, Lin CC, Dinh TK, Huang HC, Shih YC, Alson D, Lin CY, Lin YC, Chang PC, Lin SY, Chen Y) Sci Adv 2020 Jan;6(3):eaax5032 208 Citations |
| 1 | Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma. (Krook MA, Lenyo A, Wilberding M, Barker H, Dantuono M, Bailey KM, Chen HZ, Reeser JW, Wing MR, Miya J, Samorodnitsky E, Smith AM, Dao T, Martin DM, Ciombor KK, Hays J, Freud AG, Roychowdhury S) Mol Cancer Ther 2020 Mar;19(3):847-857 113 Citations |
| 1 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. (Fachal L, Aschard H, Beesley J, Barnes DR, Allen J, Kar S, Pooley KA, Dennis J, Michailidou K, Turman C, Soucy P, Lemaçon A, Lush M, Tyrer JP, Ghoussaini M, Moradi Marjaneh M, Jiang X, Agata S, Aittomäki K, Alonso MR, Andrulis IL, Anton-Culver H, Antonenkova NN, Arason A, Arndt V, Aronson KJ, Arun BK, Auber B, Auer PL, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Beeghly-Fadiel A, Benitez J, Bermisheva M, Białkowska K, Blanco AM, Blomqvist C, Blot W, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Borg A, Bosse K, Brauch H, Brenner H, Briceno I, Brock IW, Brooks-Wilson A, Brüning T, Burwinkel B, Buys SS, Cai Q, Caldés T, Caligo MA, Camp NJ, Campbell I, Canzian F, Carroll JS, Carter BD, Castelao JE, Chiquette J, Christiansen H, Chung WK, Claes KBM, Clarke CL, GEMO Study Collaborators, EMBRACE Collaborators, Collée JM, Cornelissen S, Couch FJ, Cox A, Cross SS, Cybulski C, Czene K, Daly MB, de la Hoya M, Devilee P, Diez O, Ding YC, Dite GS, Domchek SM, Dörk T, Dos-Santos-Silva I, Droit A, Dubois S, Dumont M, Duran M, Durcan L, Dwek M, Eccles DM, Engel C, Eriksson M, Evans DG, Fasching PA, Fletcher O, Floris G, Flyger H, Foretova L, Foulkes WD, Friedman E, Fritschi L, Frost D, Gabrielson M, Gago-Dominguez M, Gambino G, Ganz PA, Gapstur SM, Garber J, García-Sáenz JA, Gaudet MM, Georgoulias V, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Tibiletti MG, Greene MH, Grip M, Gronwald J, Grundy A, Guénel P, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hartikainen JM, Hartman M, He W, Healey CS, Heemskerk-Gerritsen BAM, Heyworth J, Hillemanns P, Hogervorst FBL, Hollestelle A, Hooning MJ, Hopper JL, Howell A, Huang G, Hulick PJ, Imyanitov EN, KConFab Investigators, HEBON Investigators, ABCTB Investigators, Isaacs C, Iwasaki M, Jager A, Jakimovska M, Jakubowska A, James PA, Janavicius R, Jankowitz RC, John EM, Johnson N, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kang D, Kapoor PM, Karlan BY, Keeman R, Kerin MJ, Khusnutdinova E, Kiiski JI, Kirk J, Kitahara CM, Ko YD, Konstantopoulou I, Kosma VM, Koutros S, Kubelka-Sabit K, Kwong A, Kyriacou K, Laitman Y, Lambrechts D, Lee E, Leslie G, Lester J, Lesueur F, Lindblom A, Lo WY, Long J, Lophatananon A, Loud JT, Lubiński J, MacInnis RJ, Maishman T, Makalic E, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Matsuo K, Maurer T, Mavroudis D, Mayes R, McGuffog L, McLean C, Mebirouk N, Meindl A, Miller A, Miller N, Montagna M, Moreno F, Muir K, Mulligan AM, Muñoz-Garzon VM, Muranen TA, Narod SA, Nassir R, Nathanson KL, Neuhausen SL, Nevanlinna H, Neven P, Nielsen FC, Nikitina-Zake L, Norman A, Offit K, Olah E, Olopade OI, Olsson H, Orr N, Osorio A, Pankratz VS, Papp J, Park SK, Park-Simon TW, Parsons MT, Paul J, Pedersen IS, Peissel B, Peshkin B, Peterlongo P, Peto J, Plaseska-Karanfilska D, Prajzendanc K, Prentice R, Presneau N, Prokofyeva D, Pujana MA, Pylkäs K, Radice P, Ramus SJ, Rantala J, Rau-Murthy R, Rennert G, Risch HA, Robson M, Romero A, Rossing M, Saloustros E, Sánchez-Herrero E, Sandler DP, Santamariña M, Saunders C, Sawyer EJ, Scheuner MT, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schöttker B, Schürmann P, Scott C, Scott RJ, Senter L, Seynaeve CM, Shah M, Sharma P, Shen CY, Shu XO, Singer CF, Slavin TP, Smichkoska S, Southey MC, Spinelli JJ, Spurdle AB, Stone J, Stoppa-Lyonnet D, Sutter C, Swerdlow AJ, Tamimi RM, Tan YY, Tapper WJ, Taylor JA, Teixeira MR, Tengström M, Teo SH, Terry MB, Teulé A, Thomassen M, Thull DL, Tischkowitz M, Toland AE, Tollenaar RAEM, Tomlinson I, Torres D, Torres-Mejía G, Troester MA, Truong T, Tung N, Tzardi M, Ulmer HU, Vachon CM, van Asperen CJ, van der Kolk LE, van Rensburg EJ, Vega A, Viel A, Vijai J, Vogel MJ, Wang Q, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Wildiers H, Winqvist R, Wolk A, Wu AH, Yannoukakos D, Zhang Y, Zheng W, Hunter D, Pharoah PDP, Chang-Claude J, García-Closas M, Schmidt MK, Milne RL, Kristensen VN, French ) Nat Genet 2020 Jan;52(1):56-73 117 Citations |
| 1 | Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. (Tsimberidou AM, Hong DS, Wheler JJ, Falchook GS, Janku F, Naing A, Fu S, Piha-Paul S, Cartwright C, Broaddus RR, Nogueras Gonzalez GM, Hwu P, Kurzrock R) J Hematol Oncol 2019 Dec 30;12(1):145 41 Citations |
| 1 | Expression analysis of NF-κB interacting long noncoding RNAs in breast cancer. (Dashti S, Ghafouri-Fard S, Esfandi F, Oskooei VK, Arsang-Jang S, Taheri M) Exp Mol Pathol 2020 Feb;112:104359 12 Citations |
| 1 | Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. (Patel H, Okamura R, Fanta P, Patel C, Lanman RB, Raymond VM, Kato S, Kurzrock R) J Hematol Oncol 2019 Dec 04;12(1):130 75 Citations |
| 3 | Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice? (Krepline AN, Bliss L, Geurts J, Akinola I, Christians KK, George B, Ritch PS, Hall WA, Erickson BA, Evans DB, Tsai S) J Gastrointest Surg 2020 Feb;24(2):235-242 10 Citations |
| 1 | Using a Novel Diagnostic Nomogram to Differentiate Malignant from Benign Parathyroid Neoplasms. (Silva-Figueroa AM, Bassett R Jr, Christakis I, Moreno P, Clarke CN, Busaidy NL, Grubbs EG, Lee JE, Perrier ND, Williams MD) Endocr Pathol 2019 Dec;30(4):285-296 24 Citations |
| 1 | Lymphatic-type "Angiosarcoma" With Prominent Lymphocytic Infiltrate. (Martinez AP, Zapata M, North PE, Folpe AL, Weiss SW) Am J Surg Pathol 2020 Feb;44(2):271-279 8 Citations |
| 1 | Understanding the Value of Tumor Markers in Pediatric Ovarian Neoplasms. (Lawrence AE, Fallat ME, Hewitt G, Hertweck P, Onwuka A, Afrazi A, Bence C, Burns RC, Corkum KS, Dillon PA, Ehrlich PF, Fraser JD, Gonzalez DO, Grabowski JE, Kabre R, Lal DR, Landman MP, Leys CM, Mak GZ, Overman RE, Rademacher BL, Raiji MT, Sato TT, Scannell M, Sujka JA, Wright T, Minneci PC, Deans KJ, Aldrink JH, Midwest Pediatric Surgery Consortium) J Pediatr Surg 2020 Jan;55(1):122-125 27 Citations |
| 1 | Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy. (Shee K, Wells JD, Jiang A, Miller TW) PLoS One 2019;14(11):e0224267 34 Citations |
| 2 | Molecular and Genetic Markers in Appendiceal Mucinous Tumors: A Systematic Review. (Stein A, Strong E, Clark Gamblin T, Clarke C, Tsai S, Thomas J, George B, Mogal H) Ann Surg Oncol 2020 Jan;27(1):85-97 24 Citations |
| 1 | Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues. (Li AM, Boichard A, Kurzrock R) Cancer Biol Ther 2020;21(1):95-100 38 Citations |
| 1 | A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition. (Shee K, Wells JD, Ung M, Hampsch RA, Traphagen NA, Yang W, Liu SC, Zeldenrust MA, Wang L, Kalari KR, Yu J, Boughey JC, Demidenko E, Kettenbach AN, Cheng C, Goetz MP, Miller TW) Clin Cancer Res 2020 Jan 01;26(1):159-170 1 Citation |
| 1 | Detection of Microsatellite Instability Biomarkers via Next-Generation Sequencing. (Bonneville R, Krook MA, Chen HZ, Smith A, Samorodnitsky E, Wing MR, Reeser JW, Roychowdhury S) Methods Mol Biol 2020;2055:119-132 51 Citations |
| 2 | Identification and validation of a prognostic proteomic signature for cervical cancer. (Rader JS, Pan A, Corbin B, Iden M, Lu Y, Vellano CP, Akbani R, Mills GB, Simpson P) Gynecol Oncol 2019 Nov;155(2):324-330 6 Citations |
| 1 | Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. (Nikanjam M, Arguello D, Gatalica Z, Swensen J, Barkauskas DA, Kurzrock R) Int J Cancer 2020 Jun 01;146(11):3087-3097 20 Citations |
| 1 | microRNA-21 Expression as Prognostic and Therapeutic Response Marker in Chronic Myeloid Leukaemia Patients. (Mirza MAB, Guru SA, Abdullah SM, Rizvi A, Saxena A) Asian Pac J Cancer Prev 2019 Aug 01;20(8):2379-2383 8 Citations |
| 1 | Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma. (Miller TW, Traphagen NA, Li J, Lewis LD, Lopes B, Asthagiri A, Loomba J, De Jong J, Schiff D, Patel SH, Purow BW, Fadul CE) J Neurooncol 2019 Sep;144(3):563-572 30 Citations |
| 1 | Breast Cancer Biomarkers: Challenges in Routine Estrogen Receptor, Progesterone Receptor, and HER2/neu Evaluation. (Jorns JM) Arch Pathol Lab Med 2019 Dec;143(12):1444-1449 21 Citations |
| 1 | Prognostic and clinicopathologic significance of MicroRNA-125a-5p in cancers: A meta-analysis. (Ye H, Zhu W, Mei L, Lu Z) Medicine (Baltimore) 2019 Aug;98(31):e16685 7 Citations |
| 1 | Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. (Kaseb AO, Sánchez NS, Sen S, Kelley RK, Tan B, Bocobo AG, Lim KH, Abdel-Wahab R, Uemura M, Pestana RC, Qiao W, Xiao L, Morris J, Amin HM, Hassan MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills-Shaw KR, George B, Haque A, Raghav KPS, Wolff RA, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R) Clin Cancer Res 2019 Oct 15;25(20):6107-6118 64 Citations |
| 1 | Repeat Biomarker Status in Breast Resection Specimens With Controlled Cold Ischemic Time. (East EG, Roberts E, Zhao L, Jorns JM) Am J Clin Pathol 2019 Nov 04;152(6):766-774 1 Citation |
| 1 | Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics. (Choi IS, Kato S, Fanta PT, Leichman L, Okamura R, Raymond VM, Lanman RB, Lippman SM, Kurzrock R) Mol Cancer Ther 2019 Oct;18(10):1852-1862 19 Citations |
| 1 | Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer. (Chae YK, Viveiros P, Lopes G, Sukhadia B, Sheikh MM, Saravia D, Florou V, Sokol ES, Frampton GM, Chalmers ZR, Ali SM, Ross JS, Chang S, Wang S, Chiec L, Rahbari A, Mohindra N, Villaflor V, Shin SH, Oh M, Anker J, Park LC, Wang V, Chuang J, Park W) J Thorac Oncol 2019 Oct;14(10):1807-1817 35 Citations |
| 1 | Genetic associations of breast and prostate cancer are enriched for regulatory elements identified in disease-related tissues. (Chen H, Kichaev G, Bien SA, MacDonald JW, Wang L, Bammler TK, Auer P, Pasaniuc B, Lindström S) Hum Genet 2019 Oct;138(10):1091-1104 7 Citations |
| 1 | Genomic Alterations in Undifferentiated Malignant Tumors with Rhabdoid Phenotype and Loss of BRG1 Immunoexpression Identified by Fine Needle Aspirates. (Mei L, Alikhan M, Mujacic I, Parilla M, Antic T) Acta Cytol 2019;63(5):438-444 5 Citations |
| 1 | Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan-cancer setting. (Mardinian K, Okamura R, Kato S, Kurzrock R) Int J Cancer 2020 Jan 15;146(2):566-576 17 Citations |
| 1 | A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. (Kurzrock R, Ball DW, Zahurak ML, Nelkin BD, Subbiah V, Ahmed S, O'Connor A, Karunsena E, Parkinson RM, Bishop JA, Ha Y, Sharma R, Gocke CD, Zinner R, Rudek MA, Sherman SI, Azad NS) Clin Cancer Res 2019 Sep 15;25(18):5475-5484 18 Citations |
| 3 | Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome. (Plasterer C, Tsaih SW, Peck AR, Chervoneva I, O'Meara C, Sun Y, Lemke A, Murphy D, Smith J, Ran S, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Mitchell EP, Bergom C, Joshi A, Auer P, Prokop J, Rui H, Flister MJ) Breast Cancer Res Treat 2019 Aug;177(1):77-91 5 Citations |
| 1 | Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53. (Zhong F, Zhu T, Pan X, Zhang Y, Yang H, Wang X, Hu J, Han H, Mei L, Chen D, Wang K, Zhou X, Li X, Dong X) Cancer Med 2019 Jul;8(8):3928-3935 7 Citations |
| 1 | Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer. (Adashek JJ, Junior PNA, Galanina N, Kurzrock R) J Immunother Cancer 2019 May 22;7(1):130 7 Citations |
| 1 | A Logistic Regression Model for Noninvasive Prediction of AFP-Negative Hepatocellular Carcinoma. (Luo CL, Rong Y, Chen H, Zhang WW, Wu L, Wei D, Wei XQ, Mei LJ, Wang FB) Technol Cancer Res Treat 2019 Jan 01;18:1533033819846632 19 Citations |
| 1 | Genomic correlates of clinical outcome in advanced prostate cancer. (Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera JM, Robinson BD, De Sarkar N, Kunju LP, Tomlins S, Wu YM, Nava Rodrigues D, Loda M, Gopalan A, Reuter VE, Pritchard CC, Mateo J, Bianchini D, Miranda S, Carreira S, Rescigno P, Filipenko J, Vinson J, Montgomery RB, Beltran H, Heath EI, Scher HI, Kantoff PW, Taplin ME, Schultz N, deBono JS, Demichelis F, Nelson PS, Rubin MA, Chinnaiyan AM, Sawyers CL) Proc Natl Acad Sci U S A 2019 Jun 04;116(23):11428-11436 870 Citations |
| 3 | Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma. (Samuels TL, Altman KW, Gould JC, Kindel T, Bosler M, MacKinnon A, Hagen CE, Johnston N) Laryngoscope 2019 Dec;129(12):2687-2695 17 Citations |
| 1 | Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. (Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña I, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, Martini JF, Raynaud J, Mendelsohn J, Batist G, Onn A, Tabernero J, Schilsky RL, Lazar V, Lee JJ, Kurzrock R) Nat Med 2019 May;25(5):751-758 404 Citations |
| 1 | Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness. (Goodman AM, Kato S, Chattopadhyay R, Okamura R, Saunders IM, Montesion M, Frampton GM, Miller VA, Daniels GA, Kurzrock R) Cancer Immunol Res 2019 Jun;7(6):866-873 22 Citations |
| 1 | BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells. (Zhang X, Wang Y, Chiang HC, Hsieh YP, Lu C, Park BH, Jatoi I, Jin VX, Hu Y, Li R) Breast Cancer Res 2019 Apr 17;21(1):51 18 Citations |
| 1 | Encapsulated and solid papillary carcinomas of the breast: Tumors in transition from in situ to invasive? (Solanki MH, Derylo AF, Visotcky AM, Jorns JM) Breast J 2019 May;25(3):539-541 5 Citations |
| 1 | Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer. (Jahan R, Ganguly K, Smith LM, Atri P, Carmicheal J, Sheinin Y, Rachagani S, Natarajan G, Brand RE, Macha MA, Grandgenett PM, Kaur S, Batra SK) EBioMedicine 2019 Apr;42:375-385 36 Citations |
| 2 | SOX11 hypermethylation as a tumor biomarker in endometrial cancer. (Shan T, Uyar DS, Wang LS, Mutch DG, Huang TH, Rader JS, Sheng X, Huang YW) Biochimie 2019 Jul;162:8-14 14 Citations |
| 1 | Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies. (Shatsky R, Parker BA, Bui NQ, Helsten T, Schwab RB, Boles SG, Kurzrock R) Mol Cancer Ther 2019 May;18(5):1001-1011 33 Citations |
| 1 | Expression of long non-coding RNAs (lncRNAs) has been dysregulated in non-small cell lung cancer tissues. (Esfandi F, Taheri M, Omrani MD, Shadmehr MB, Arsang-Jang S, Shams R, Ghafouri-Fard S) BMC Cancer 2019 Mar 12;19(1):222 45 Citations |
| 1 | Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. (Schweizer MT, Gulati R, Beightol M, Konnick EQ, Cheng HH, Klemfuss N, De Sarkar N, Yu EY, Montgomery RB, Nelson PS, Pritchard CC) Prostate 2019 May;79(7):701-708 23 Citations |
| 1 | Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. (Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N) Gastroenterology 2019 Jun;156(8):2242-2253.e4 245 Citations |
| 1 | GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. (Brooks RA, Tritchler DS, Darcy KM, Lankes HA, Salani R, Sperduto P, Guntupalli S, DiSilvestro P, Kesterson J, Olawaiye AB, Moxley K, Waggoner S, Santin A, Rader JS, Kizer NT, Thaker PH, Powell MA, Mutch DG, Birrer MJ, Goodfellow PJ) Gynecol Oncol 2019 May;153(2):335-342 6 Citations |
| 1 | The Promising Signatures of Circulating microRNA-145 in Epithelial Ovarian Cancer Patients. (Zuberi M, Mir R, Khan I, Javid J, Guru SA, Bhat M, Sumi MP, Ahmad I, Masroor M, Yadav P, Vishnubhatla S, Saxena A) Microrna 2020;9(1):49-57 |
| 1 | No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study. (Dong J, Gharahkhani P, Chow WH, Gammon MD, Liu G, Caldas C, Wu AH, Ye W, Onstad L, Anderson LA, Bernstein L, Pharoah PD, Risch HA, Corley DA, Fitzgerald RC, Stomach and Esophageal Cancer Study Consortium, Iyer PG, Reid BJ, Lagergren J, Shaheen NJ, Vaughan TL, MacGregor S, Love S, Palles C, Tomlinson I, Gockel I, May A, Gerges C, Anders M, Böhmer AC, Becker J, Kreuser N, Thieme R, Noder T, Venerito M, Veits L, Schmidt T, Schmidt C, Izbicki JR, Hölscher AH, Lang H, Lorenz D, Schumacher B, Mayershofer R, Vashist Y, Ott K, Vieth M, Weismüller J, Nöthen MM, Moebus S, Knapp M, Peters WHM, Neuhaus H, Rösch T, Ell C, Jankowski J, Schumacher J, Neale RE, Whiteman DC, Thrift AP) Clin Gastroenterol Hepatol 2019 Oct;17(11):2227-2235.e1 18 Citations |
| 1 | Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue. (Shuen AY, Lanni S, Panigrahi GB, Edwards M, Yu L, Campbell BB, Mandel A, Zhang C, Zhukova N, Alharbi M, Bernstein M, Bowers DC, Carroll S, Cole KA, Constantini S, Crooks B, Dvir R, Farah R, Hijiya N, George B, Laetsch TW, Larouche V, Lindhorst S, Luiten RC, Magimairajan V, Mason G, Mason W, Mordechai O, Mushtaq N, Nicholas G, Oren M, Palma L, Pedroza LA, Ramdas J, Samuel D, Wolfe Schneider K, Seeley A, Semotiuk K, Shamvil A, Sumerauer D, Toledano H, Tomboc P, Wierman M, Van Damme A, Lee YY, Zapotocky M, Bouffet E, Durno C, Aronson M, Gallinger S, Foulkes WD, Malkin D, Tabori U, Pearson CE) J Clin Oncol 2019 Feb 20;37(6):461-470 27 Citations |
| 1 | Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes. (Tray N, Taff J, Singh B, Suh J, Ngo N, Kwa M, Troxel AB, Chae YK, Kurzrock R, Patel SP, Sharon E, Denkert C, Ross JS, Adams S) Breast 2019 Apr;44:29-32 45 Citations |
| 1 | Identification and targeting of novel CDK9 complexes in acute myeloid leukemia. (Beauchamp EM, Abedin SM, Radecki SG, Fischietti M, Arslan AD, Blyth GT, Yang A, Lantz C, Nelson A, Goo YA, Akpan I, Eklund EA, Frankfurt O, Fish EN, Thomas PM, Altman JK, Platanias LC) Blood 2019 Mar 14;133(11):1171-1185 31 Citations |
| 1 | Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. (Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R) Eur J Cancer 2019 Jan;107:142-152 202 Citations |
| 1 | Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients. (Jensen TJ, Goodman AM, Kato S, Ellison CK, Daniels GA, Kim L, Nakashe P, McCarthy E, Mazloom AR, McLennan G, Grosu DS, Ehrich M, Kurzrock R) Mol Cancer Ther 2019 Feb;18(2):448-458 65 Citations |
| 1 | Neutrophil Gelatinase-associated Lipocalin as a Theragnostic Marker in Perihilar Cholangiocarcinoma. (Nair A, Ingram N, Verghese ET, Wijetunga I, Markham AF, Wyatt J, Prasad KR, Coletta PL) Anticancer Res 2018 Dec;38(12):6737-6744 6 Citations |
| 1 | Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing. (Shee K, Muller KE, Marotti J, Miller TW, Wells WA, Tsongalis GJ) Am J Pathol 2019 May;189(5):956-965 19 Citations |
| 1 | Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. (Pavel ME, Phan AT, Wolin EM, Mirakhur B, Liyanage N, Pitman Lowenthal S, Fisher GA Jr, Vinik AI, CLARINET Study Investigators) Oncologist 2019 Apr;24(4):463-474 15 Citations |
| 1 | Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. (Kato S, Okamura R, Baumgartner JM, Patel H, Leichman L, Kelly K, Sicklick JK, Fanta PT, Lippman SM, Kurzrock R) Clin Cancer Res 2018 Dec 15;24(24):6248-6256 91 Citations |
| 1 | Oleuropein inhibits migration ability through suppression of epithelial-mesenchymal transition and synergistically enhances doxorubicin-mediated apoptosis in MCF-7 cells. (Choupani J, Alivand MR, M Derakhshan S, Zaeifizadeh M, S Khaniani M) J Cell Physiol 2019 Jun;234(6):9093-9104 30 Citations |
| 5 | Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. (Tsai S, George B, Wittmann D, Ritch PS, Krepline AN, Aldakkak M, Barnes CA, Christians KK, Dua K, Griffin M, Hagen C, Hall WA, Erickson BA, Evans DB) Ann Surg 2020 Apr;271(4):740-747 138 Citations |
| 1 | Considering the downregulation of Tpm1.6 and Tpm1.7 in squamous cell carcinoma of esophagus as a potent biomarker. (Zare M, Hadi F, Alivand MR) Per Med 2018 Sep;15(5):361-370 1 Citation |
| 4 | Low-Temperature EPR Spectroscopy as a Probe-Free Technique for Monitoring Oxidants Formed in Tumor Cells and Tissues: Implications in Drug Resistance and OXPHOS-Targeted Therapies. (Kalyanaraman B, Cheng G, Zielonka J, Bennett B) Cell Biochem Biophys 2019 Mar;77(1):89-98 13 Citations |
| 1 | Management of Neuroendocrine Tumors in the Twenty-First Century. (Ioachimescu AG) Endocrinol Metab Clin North Am 2018 Sep;47(3):xiii-xiv 4 Citations |
| 1 | Identification of nine new susceptibility loci for endometrial cancer. (O'Mara TA, Glubb DM, Amant F, Annibali D, Ashton K, Attia J, Auer PL, Beckmann MW, Black A, Bolla MK, Brauch H, Brenner H, Brinton L, Buchanan DD, Burwinkel B, Chang-Claude J, Chanock SJ, Chen C, Chen MM, Cheng THT, Clarke CL, Clendenning M, Cook LS, Couch FJ, Cox A, Crous-Bous M, Czene K, Day F, Dennis J, Depreeuw J, Doherty JA, Dörk T, Dowdy SC, Dürst M, Ekici AB, Fasching PA, Fridley BL, Friedenreich CM, Fritschi L, Fung J, García-Closas M, Gaudet MM, Giles GG, Goode EL, Gorman M, Haiman CA, Hall P, Hankison SE, Healey CS, Hein A, Hillemanns P, Hodgson S, Hoivik EA, Holliday EG, Hopper JL, Hunter DJ, Jones A, Krakstad C, Kristensen VN, Lambrechts D, Marchand LL, Liang X, Lindblom A, Lissowska J, Long J, Lu L, Magliocco AM, Martin L, McEvoy M, Meindl A, Michailidou K, Milne RL, Mints M, Montgomery GW, Nassir R, Olsson H, Orlow I, Otton G, Palles C, Perry JRB, Peto J, Pooler L, Prescott J, Proietto T, Rebbeck TR, Risch HA, Rogers PAW, Rübner M, Runnebaum I, Sacerdote C, Sarto GE, Schumacher F, Scott RJ, Setiawan VW, Shah M, Sheng X, Shu XO, Southey MC, Swerdlow AJ, Tham E, Trovik J, Turman C, Tyrer JP, Vachon C, VanDen Berg D, Vanderstichele A, Wang Z, Webb PM, Wentzensen N, Werner HMJ, Winham SJ, Wolk A, Xia L, Xiang YB, Yang HP, Yu H, Zheng W, Pharoah PDP, Dunning AM, Kraft P, De Vivo I, Tomlinson I, Easton DF, Spurdle AB, Thompson DJ) Nat Commun 2018 Aug 09;9(1):3166 173 Citations |
| 5 | A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. (Tsai S, Christians KK, George B, Ritch PS, Dua K, Khan A, Mackinnon AC, Tolat P, Ahmad SA, Hall WA, Erickson BA, Evans DB) Ann Surg 2018 Oct;268(4):610-619 64 Citations |
| 1 | Characterizing parathyroid carcinomas and atypical neoplasms based on the expression of programmed death-ligand 1 expression and the presence of tumor-infiltrating lymphocytes and macrophages. (Silva-Figueroa A, Villalobos P, Williams MD, Bassett RL Jr, Clarke CN, Lee JE, Busaidy NL, Perrier ND) Surgery 2018 Nov;164(5):960-964 18 Citations |
| 1 | Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival. (Baumgartner JM, Raymond VM, Lanman RB, Tran L, Kelly KJ, Lowy AM, Kurzrock R) Ann Surg Oncol 2018 Aug;25(8):2400-2408 51 Citations |
| 1 | Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. (Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller V, Sicklick JK, Kurzrock R) JAMA Oncol 2018 Sep 01;4(9):1237-1244 206 Citations |
| 1 | Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance. (Nguyen HS, Shabani S, Awad AJ, Kaushal M, Doan N) Int J Mol Sci 2018 Jun 14;19(6) 45 Citations |
| 1 | Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients. (Kohli M, Li J, Du M, Hillman DW, Dehm SM, Tan W, Carlson R, Campion MB, Wang L, Wang L, Zhang H, Zhang P, Kilari D, Huang CC, Wang L) Prostate Cancer Prostatic Dis 2018 Sep;21(3):411-418 30 Citations |
| 1 | Implementing precision cancer medicine in the genomic era. (Chen HZ, Bonneville R, Roychowdhury S) Semin Cancer Biol 2019 Apr;55:16-27 26 Citations |
| 3 | Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. (Lomberk G, Blum Y, Nicolle R, Nair A, Gaonkar KS, Marisa L, Mathison A, Sun Z, Yan H, Elarouci N, Armenoult L, Ayadi M, Ordog T, Lee JH, Oliver G, Klee E, Moutardier V, Gayet O, Bian B, Duconseil P, Gilabert M, Bigonnet M, Garcia S, Turrini O, Delpero JR, Giovannini M, Grandval P, Gasmi M, Secq V, De Reyniès A, Dusetti N, Iovanna J, Urrutia R) Nat Commun 2018 May 17;9(1):1978 183 Citations |
| 1 | Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance. (Du M, Thompson J, Fisher H, Zhang P, Huang CC, Wang L) Lung Cancer 2018 Jun;120:113-121 40 Citations |
| 1 | Liquid Biopsies and Cancer Immunotherapy. (Thompson JR, Menon SP) Cancer J 2018;24(2):78-83 18 Citations |
| 4 | Early Fluorescence in situ Hybridization Assessment during Acute Myeloid Leukemia Induction Chemotherapy. (Schneidewend R, Hosking P, Brazauskas R, Peterson J, Beaudin C, Michaelis L, Atallah E, Hari P, Carlson K) Acta Haematol 2018;139(3):171-175 |
| 1 | Invasive Mammary Carcinoma With Mixed Invasive Papillary and Glycogen Rich Clear Cell Features. (Solanki MH, Derylo AF, Jorns JM) Int J Surg Pathol 2018 Sep;26(6):569-572 3 Citations |
| 1 | Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. (Ikeda S, Tsigelny IF, Skjevik ÅA, Kono Y, Mendler M, Kuo A, Sicklick JK, Heestand G, Banks KC, Talasaz A, Lanman RB, Lippman S, Kurzrock R) Oncologist 2018 May;23(5):586-593 70 Citations |
| 1 | A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer. (Rudolph M, Sizemore ST, Lu Y, Teng KY, Basree MM, Reinbolt R, Timmers CD, Leone G, Ostrowski MC, Majumder S, Ramaswamy B) Breast Cancer Res Treat 2018 Jun;169(3):457-467 8 Citations |
| 1 | Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. (Schrock AB, Pavlick D, Klempner SJ, Chung JH, Forcier B, Welsh A, Young L, Leyland-Jones B, Bordoni R, Carvajal RD, Chao J, Kurzrock R, Sicklick JK, Ross JS, Stephens PJ, Devoe C, Braiteh F, Ali SM, Miller VA) Clin Cancer Res 2018 Apr 15;24(8):1881-1890 57 Citations |
| 1 | The microRNA landscape of cutaneous squamous cell carcinoma. (Konicke K, López-Luna A, Muñoz-Carrillo JL, Servín-González LS, Flores-de la Torre A, Olasz E, Lazarova Z) Drug Discov Today 2018 Apr;23(4):864-870 28 Citations |
| 1 | Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors. (Jardim DL, de Melo Gagliato D, Giles FJ, Kurzrock R) Clin Cancer Res 2018 Apr 15;24(8):1785-1794 46 Citations |
| 1 | Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients. (Schwaederle M, Krishnamurthy N, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Patel SP, Parker BA, Kurzrock R) Cancer 2018 Mar 15;124(6):1288-1296 23 Citations |
| 5 | Characterizing indeterminate liver lesions in patients with localized pancreatic cancer at the time of diagnosis. (Bhalla M, Aldakkak M, Kulkarni NM, O'Connor SD, Griffin MO Jr, Christians KK, Evans DB, Tsai S, Tolat PP) Abdom Radiol (NY) 2018 Feb;43(2):351-363 12 Citations |
| 1 | Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen. (McFall T, McKnight B, Rosati R, Kim S, Huang Y, Viola-Villegas N, Ratnam M) J Biol Chem 2018 Jan 26;293(4):1163-1177 34 Citations |
| 1 | Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). (Mitamura T, Pradeep S, McGuire M, Wu SY, Ma S, Hatakeyama H, Lyons YA, Hisamatsu T, Noh K, Villar-Prados A, Chen X, Ivan C, Rodriguez-Aguayo C, Hu W, Lopez-Berestein G, Coleman RL, Sood AK) Oncogene 2018 Feb 08;37(6):722-731 33 Citations |
| 1 | Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach. (Kato S, Kurasaki K, Ikeda S, Kurzrock R) Oncologist 2018 Feb;23(2):171-178 33 Citations |
| 1 | Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. (Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R) Clin Cancer Res 2017 Oct 01;23(19):5729-5736 175 Citations |
| 1 | Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. (Clarke CN, Lee MS, Wei W, Manyam G, Jiang ZQ, Lu Y, Morris J, Broom B, Menter D, Vilar-Sanchez E, Raghav K, Eng C, Chang GJ, Simon I, Bernards R, Overman M, Mills GB, Maru D, Kopetz S) Ann Surg Oncol 2017 Dec;24(13):4051-4058 26 Citations |
| 1 | Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability. (Bieg-Bourne CC, Millis SZ, Piccioni DE, Fanta PT, Goldberg ME, Chmielecki J, Parker BA, Kurzrock R) Cancer Res 2017 Nov 15;77(22):6313-6320 24 Citations |
| 1 | The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. (Khemlina G, Ikeda S, Kurzrock R) Mol Cancer 2017 Aug 30;16(1):149 324 Citations |
| 2 | Evaluation of CD43 expression in non-hematopoietic malignancies. (Batdorf BH, Kroft SH, Hosking PR, Harrington AM, Mackinnon AC, Olteanu H) Ann Diagn Pathol 2017 Aug;29:23-27 10 Citations |
| 1 | Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. (Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Banks KC, Choi IS, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R) Cancer Res 2017 Oct 01;77(19):5419-5427 89 Citations |
| 1 | Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients. (Heestand GM, Schwaederle M, Gatalica Z, Arguello D, Kurzrock R) Eur J Cancer 2017 Sep;83:80-87 57 Citations |
| 3 | Sucrose Non-Fermenting Related Kinase Expression in Ovarian Cancer and Correlation with Clinical Features. (Hopp EE, Cossette SM, Kumar SN, Eastwood D, Ramchandran R, Bishop E) Cancer Invest 2017 Aug 09;35(7):456-462 4 Citations |
| 1 | Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit. (Kato S, Subbiah V, Kurzrock R) J Natl Compr Canc Netw 2017 Jul;15(7):863-866 22 Citations |
| 1 | Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. (Halle MK, Ojesina AI, Engerud H, Woie K, Tangen IL, Holst F, Høivik E, Kusonmano K, Haldorsen IS, Vintermyr OK, Trovik J, Bertelsen BI, Salvesen HB, Krakstad C) Am J Obstet Gynecol 2017 Oct;217(4):432.e1-432.e17 43 Citations |
| 1 | Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. (Schwaederlé MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, Talasaz A, Bazhenova L, Kurzrock R) Clin Cancer Res 2017 Sep 01;23(17):5101-5111 123 Citations |
| 1 | Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options. (Moskovitz JM, Moy J, Seiwert TY, Ferris RL) Oncologist 2017 Jun;22(6):680-693 24 Citations |
| 2 | PTEN loss and p27 loss differ among morphologic patterns of prostate cancer, including cribriform. (Ronen S, Abbott DW, Kravtsov O, Abdelkader A, Xu Y, Banerjee A, Iczkowski KA) Hum Pathol 2017 Jul;65:85-91 35 Citations |
| 1 | PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison. (Sunshine JC, Nguyen PL, Kaunitz GJ, Cottrell TR, Berry S, Esandrio J, Xu H, Ogurtsova A, Bleich KB, Cornish TC, Lipson EJ, Anders RA, Taube JM) Clin Cancer Res 2017 Aug 15;23(16):4938-4944 126 Citations |
| 2 | Systemic Anaplastic Lymphoma Kinase-positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival. (Guru Murthy GS, Hamadani M, Bhatt VR, Dhakal I, Mehta P) Clin Lymphoma Myeloma Leuk 2017 Apr;17(4):201-206 12 Citations |
| 1 | Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. (Previs RA, Armaiz-Pena GN, Ivan C, Dalton HJ, Rupaimoole R, Hansen JM, Lyons Y, Huang J, Haemmerle M, Wagner MJ, Gharpure KM, Nagaraja AS, Filant J, McGuire MH, Noh K, Dorniak PL, Linesch SL, Mangala LS, Pradeep S, Wu SY, Sood AK) J Natl Cancer Inst 2017 Jul 01;109(7) 12 Citations |
| 1 | Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. (Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R) Clin Cancer Res 2017 Aug 01;23(15):4242-4250 722 Citations |
| 1 | Fine mapping of chromosome 5p15.33 identifies novel lung cancer susceptibility loci in Han Chinese. (Dong J, Cheng Y, Zhu M, Wen Y, Wang C, Wang Y, Geng L, Shen W, Liu J, Li Z, Zhang J, Ma H, Dai J, Jin G, Hu Z, Shen H) Int J Cancer 2017 Aug 01;141(3):447-456 17 Citations |
| 1 | Retroperitoneal lymphangioleiomyoma with lymph node involvement: A pathologic-radiologic correlation of a rare form of myomelanocytic tumor. (Abdelkader A, Lam CA, Shahir KS, Christians K, Suster SM) Ann Diagn Pathol 2017 Apr;27:69-73 4 Citations |
| 1 | Rediscovering scavenger receptor type BI: surprising new roles for the HDL receptor. (Hoekstra M, Sorci-Thomas M) Curr Opin Lipidol 2017 Jun;28(3):255-260 20 Citations |
| 1 | A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. (Rader JS, Sill MW, Beumer JH, Lankes HA, Benbrook DM, Garcia F, Trimble C, Tate Thigpen J, Lieberman R, Zuna RE, Leath CA 3rd, Spirtos NM, Byron J, Thaker PH, Lele S, Alberts D) Gynecol Oncol 2017 May;145(2):291-297 19 Citations |
| 1 | Extracellular Superoxide Dismutase Expression in Papillary Thyroid Cancer Mesenchymal Stem/Stromal Cells Modulates Cancer Cell Growth and Migration. (Parascandolo A, Rappa F, Cappello F, Kim J, Cantu DA, Chen H, Mazzoccoli G, Hematti P, Castellone MD, Salvatore M, Laukkanen MO) Sci Rep 2017 Feb 20;7:41416 32 Citations |
| 1 | Salivary MMP-9 in the detection of oral squamous cell carcinoma. (Peisker A, Raschke GF, Fahmy MD, Guentsch A, Roshanghias K, Hennings J, Schultze-Mosgau S) Med Oral Patol Oral Cir Bucal 2017 May 01;22(3):e270-275 43 Citations |
| 1 | Embryonic Origin of Primary Colon Cancer Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colon Cancer Liver Metastases. (Yamashita S, Brudvik KW, Kopetz SE, Maru D, Clarke CN, Passot G, Conrad C, Chun YS, Aloia TA, Vauthey JN) Ann Surg 2018 Mar;267(3):514-520 64 Citations |
| 1 | Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. (Chang S, Zhang P, Cairncross JG, Gilbert MR, Bahary JP, Dolinskas CA, Chakravarti A, Aldape KD, Bell EH, Schiff D, Jaeckle K, Brown PD, Barger GR, Werner-Wasik M, Shih H, Brachman D, Penas-Prado M, Robins HI, Belanger K, Schultz C, Hunter G, Mehta M) Neuro Oncol 2017 Feb 01;19(2):252-258 67 Citations |
| 1 | Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With Radiotherapy. (Hall WA, Lawton CA, Jani AB, Pollack A, Feng FY) Semin Radiat Oncol 2017 Jan;27(1):11-20 11 Citations |
| 1 | Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample. (Griggs JJ, Hamilton AS, Schwartz KL, Zhao W, Abrahamse PH, Thomas DG, Jorns JM, Jewell R, Saber ME, Haque R, Katz SJ) Breast Cancer Res Treat 2017 Jan;161(2):375-384 22 Citations |
| 1 | Next generation predictive biomarkers for immune checkpoint inhibition. (Khagi Y, Kurzrock R, Patel SP) Cancer Metastasis Rev 2017 Mar;36(1):179-190 80 Citations |
| 1 | Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT. (Abu Zaid M, Wu J, Wu C, Logan BR, Yu J, Cutler C, Antin JH, Paczesny S, Choi SW) Blood 2017 Jan 12;129(2):162-170 63 Citations |
| 1 | Computational Methods and Correlation of Exon-skipping Events with Splicing, Transcription, and Epigenetic Factors. (Wang J, Ye Z, Huang TH, Shi H, Jin VX) Methods Mol Biol 2017;1513:163-170 13 Citations |
| 3 | The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. (Artz AS, Logan B, Zhu X, Akpek G, Bufarull RM, Gupta V, Lazarus HM, Litzow M, Loren A, Majhail NS, Maziarz RT, McCarthy P, Popat U, Saber W, Spellman S, Ringden O, Wickrema A, Pasquini MC, Cooke KR, from the Center for International Blood and Marrow Transplantation Research) Haematologica 2016 Nov;101(11):1426-1433 57 Citations |
| 1 | Benign müllerian glandular inclusions in men undergoing pelvic lymph node dissection. (Gallan AJ, Antic T) Hum Pathol 2016 Nov;57:136-139 15 Citations |
| 2 | Applications of Extracellular RNAs in Oncology. (Thompson JR, Zhu J, Kilari D, Wang L) Mol Diagn Ther 2017 Feb;21(1):1-11 2 Citations |
| 1 | Bringing Blood-Based Molecular Testing to the Clinic. (Janku F, Kurzrock R) Clin Cancer Res 2016 Nov 15;22(22):5400-5402 8 Citations |
| 1 | Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4. (Harjes U, Bridges E, Gharpure KM, Roxanis I, Sheldon H, Miranda F, Mangala LS, Pradeep S, Lopez-Berestein G, Ahmed A, Fielding B, Sood AK, Harris AL) Oncogene 2017 Feb 16;36(7):912-921 58 Citations |
| 1 | Genomic Landscape of Malignant Mesotheliomas. (Kato S, Tomson BN, Buys TP, Elkin SK, Carter JL, Kurzrock R) Mol Cancer Ther 2016 Oct;15(10):2498-2507 71 Citations |
| 1 | Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer. (Duran R, Mirpour S, Pekurovsky V, Ganapathy-Kanniappan S, Brayton CF, Cornish TC, Gorodetski B, Reyes J, Chapiro J, Schernthaner RE, Frangakis C, Lin M, Sun JD, Hart CP, Geschwind JF) Clin Cancer Res 2017 Jan 15;23(2):536-548 28 Citations |
| 2 | Immunophenotypes of Chronic Myelomonocytic Leukemia (CMML) Subtypes by Flow Cytometry: A Comparison of CMML-1 vs CMML-2, Myeloproliferative vs Dysplastic, De Novo vs Therapy-Related, and CMML-Specific Cytogenetic Risk Subtypes. (Harrington AM, Schelling LA, Ordobazari A, Olteanu H, Hosking PR, Kroft SH) Am J Clin Pathol 2016 Aug;146(2):170-81 13 Citations |
| 1 | Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. (Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, Mendelsohn J, Kurzrock R) JAMA Oncol 2016 Nov 01;2(11):1452-1459 274 Citations |
| 1 | Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. (Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong DS, Kurzrock R) Cancer Res 2016 Jul 01;76(13):3690-701 195 Citations |
| 1 | Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer. (Chamberlin MD, Bernhardt EB, Miller TW) J Cell Biochem 2016 Nov;117(11):2454-63 10 Citations |
| 1 | Clinicopathologic characteristics and survival of patients with gynecologic malignancies metastatic to the brain. (Divine LM, Kizer NT, Hagemann AR, Pittman ME, Chen L, Powell MA, Mutch DG, Rader JS, Thaker PH) Gynecol Oncol 2016 Jul;142(1):76-82 27 Citations |
| 1 | Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the Diagnosis. (Subbiah V, Kurzrock R) JAMA Oncol 2016 Jun 01;2(6):719-20 35 Citations |
| 1 | Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics. (Cohen PR, Tomson BN, Elkin SK, Marchlik E, Carter JL, Kurzrock R) Oncotarget 2016 Apr 26;7(17):23454-67 36 Citations |
| 1 | Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. (Rytelewski M, Maleki Vareki S, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick JD) Oncotarget 2016 Apr 12;7(15):20825-39 8 Citations |
| 1 | Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. (Dwivedi SK, Mustafi SB, Mangala LS, Jiang D, Pradeep S, Rodriguez-Aguayo C, Ling H, Ivan C, Mukherjee P, Calin GA, Lopez-Berestein G, Sood AK, Bhattacharya R) Oncotarget 2016 Mar 22;7(12):15093-104 71 Citations |
| 1 | Response. (Jardim DL, Schwaederle M, Lee JJ, Wei C, Mendelsohn J, Schilsky RL, Kurzrock R) J Natl Cancer Inst 2016 Mar;108(3):djw001 1 Citation |
| 1 | Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. (Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R) Mol Cancer Ther 2016 Apr;15(4):743-52 148 Citations |
| 1 | Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. (Sicklick JK, Fanta PT, Shimabukuro K, Kurzrock R) Cancer Metastasis Rev 2016 Jun;35(2):263-75 54 Citations |
| 1 | Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients. (Kilari D, Iczkowski KA, Pandya C, Robin AJ, Messing EM, Guancial E, Kim ES) Anticancer Res 2016 Feb;36(2):495-501 45 Citations |
| 1 | Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. (Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Banks KC, Lanman RB, Talasaz A, Parker BA, Kurzrock R) Oncotarget 2016 Mar 01;7(9):9707-17 123 Citations |
| 1 | Heterologous Liposarcomatous Differentiation in Malignant Phyllodes Tumor is Histologically Similar but Immunohistochemically and Molecularly Distinct from Well-differentiated Liposarcoma of Soft Tissue. (Inyang A, Thomas DG, Jorns J) Breast J 2016 May;22(3):282-6 23 Citations |
| 1 | Role of Increased n-acetylaspartate Levels in Cancer. (Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Eli MB, Lopez-Berestein G, Nagrath D, Bhattacharya PK, Sood AK) J Natl Cancer Inst 2016 Jan 26;108(6):djv426 55 Citations |
| 1 | Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence. (Sunkel B, Wu D, Chen Z, Wang CM, Liu X, Ye Z, Horning AM, Liu J, Mahalingam D, Lopez-Nicora H, Lin CL, Goodfellow PJ, Clinton SK, Jin VX, Chen CL, Huang TH, Wang Q) Nucleic Acids Res 2016 May 19;44(9):4105-22 33 Citations |
| 1 | Precision medicine: lessons learned from the SHIVA trial. (Tsimberidou AM, Kurzrock R) Lancet Oncol 2015 Dec;16(16):e579-80 48 Citations |
| 1 | Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options. (Ang C, Miura JT, Gamblin TC, He R, Xiu J, Millis SZ, Gatalica Z, Reddy SK, Yee NS, Abou-Alfa GK) J Surg Oncol 2016 Jan;113(1):55-61 26 Citations |
| 1 | Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer. (Branham MT, Campoy E, Laurito S, Branham R, Urrutia G, Orozco J, Gago F, Urrutia R, Roqué M) Breast Cancer Res Treat 2016 Jan;155(1):13-23 12 Citations |
| 1 | A-kinase anchor protein 4 (AKAP4) a promising therapeutic target of colorectal cancer. (Jagadish N, Parashar D, Gupta N, Agarwal S, Purohit S, Kumar V, Sharma A, Fatima R, Topno AP, Shaha C, Suri A) J Exp Clin Cancer Res 2015 Nov 21;34:142 42 Citations |
| 1 | Utility of estrogen receptor, progesterone receptor, and HER-2/neu analysis of multiple foci in multifocal ipsilateral invasive breast carcinoma. (East EG, Pang JC, Kidwell KM, Jorns JM) Am J Clin Pathol 2015 Dec;144(6):952-9 9 Citations |
| 1 | NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. (Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE 3rd, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ Jr, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM) J Natl Compr Canc Netw 2015 Nov;13(11):1337-46 21 Citations |
| 1 | PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. (Cimino-Mathews A, Thompson E, Taube JM, Ye X, Lu Y, Meeker A, Xu H, Sharma R, Lecksell K, Cornish TC, Cuka N, Argani P, Emens LA) Hum Pathol 2016 Jan;47(1):52-63 291 Citations |
| 1 | A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma. (Zhu P, Jin J, Liao Y, Li J, Yu XZ, Liao W, He S) Oncotarget 2015 Dec 01;6(38):41383-97 32 Citations |
| 4 | Improving Detection of Metastatic Neuroblastoma in Bone Marrow Core Biopsies: A Proposed Immunohistochemical Approach. (Parsons LN, Gheorghe G, Yan K, Simpson P, Jarzembowski JA) Pediatr Dev Pathol 2016;19(3):230-6 11 Citations |
| 1 | Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. (Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R) Oncotarget 2015 Oct 20;6(32):32602-9 16 Citations |
| 2 | IL17 Functions through the Novel REG3β-JAK2-STAT3 Inflammatory Pathway to Promote the Transition from Chronic Pancreatitis to Pancreatic Cancer. (Loncle C, Bonjoch L, Folch-Puy E, Lopez-Millan MB, Lac S, Molejon MI, Chuluyan E, Cordelier P, Dubus P, Lomberk G, Urrutia R, Closa D, Iovanna JL) Cancer Res 2015 Nov 15;75(22):4852-62 98 Citations |
| 1 | Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. (Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R) J Natl Cancer Inst 2015 Nov;107(11) 163 Citations |
| 3 | Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy. (Potkonjak M, Miura JT, Turaga KK, Johnston FM, Tsai S, Christians KK, Gamblin TC) HPB (Oxford) 2015 Dec;17(12):1119-23 12 Citations |
| 1 | Genetic Variants That Predispose to DNA Double-Strand Breaks in Lymphocytes From a Subset of Patients With Familial Colorectal Carcinomas. (Arora S, Yan H, Cho I, Fan HY, Luo B, Gai X, Bodian DL, Vockley JG, Zhou Y, Handorf EA, Egleston BL, Andrake MD, Nicolas E, Serebriiskii IG, Yen TJ, Hall MJ, Golemis EA, Enders GH) Gastroenterology 2015 Dec;149(7):1872-1883.e9 29 Citations |
| 1 | DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence. (Horning AM, Awe JA, Wang CM, Liu J, Lai Z, Wang VY, Jadhav RR, Louie AD, Lin CL, Kroczak T, Chen Y, Jin VX, Abboud-Werner SL, Leach RJ, Hernandez J, Thompson IM, Saranchuk J, Drachenberg D, Chen CL, Mai S, Huang TH) Prostate 2015 Nov;75(15):1790-801 22 Citations |
| 2 | The Triple-Code Model for Pancreatic Cancer: Cross Talk Among Genetics, Epigenetics, and Nuclear Structure. (Lomberk GA, Urrutia R) Surg Clin North Am 2015 Oct;95(5):935-52 22 Citations |
| 4 | Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. (Aldakkak M, Christians KK, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Evans DB, Tsai S) HPB (Oxford) 2015 Oct;17(10):942-52 52 Citations |
| 1 | Genomic landscape of salivary gland tumors. (Kato S, Elkin SK, Schwaederle M, Tomson BN, Helsten T, Carter JL, Kurzrock R) Oncotarget 2015 Sep 22;6(28):25631-45 45 Citations |
| 4 | Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. (Miura JT, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Oshima K, Christians KK, Evans DB, Tsai S) Surgery 2015 Dec;158(6):1545-55 29 Citations |
| 1 | Molecular landscape of prostate cancer: implications for current clinical trials. (Khemlina G, Ikeda S, Kurzrock R) Cancer Treat Rev 2015 Nov;41(9):761-6 59 Citations |
| 1 | Green tea component epigallocatechin-3-gallate decreases expression of osteopontin via a decrease in mRNA half-life in cell lines of metastatic hepatocellular carcinoma. (Zapf MA, Kothari AN, Weber CE, Arffa ML, Wai PY, Driver J, Gupta GN, Kuo PC, Mi Z) Surgery 2015 Oct;158(4):1039-47; discussion 1047-8 14 Citations |
| 1 | Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps. (Cobain EF, Chinnaiyan AM, Kurzrock R, Baker LH) JAMA Oncol 2015 Jul;1(4):542 1 Citation |
| 1 | Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. (Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA) JAMA Oncol 2015 Apr;1(1):80-7 511 Citations |
| 1 | Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. (Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA, Akmal O, Janku F, Kurzrock R) Oncotarget 2015 Sep 29;6(29):28453-62 12 Citations |
| 1 | A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. (Hong DS, Rosen P, Lockhart AC, Fu S, Janku F, Kurzrock R, Khan R, Amore B, Caudillo I, Deng H, Hwang YC, Loberg R, Ngarmchamnanrith G, Beaupre DM, Lee P) Oncotarget 2015 Jul 30;6(21):18693-706 25 Citations |
| 1 | Challenges to clinical utilization of hereditary cancer gene panel testing: perspectives from the front lines. (Marcus RK, Geurts JL, Grzybowski JA, Turaga KK, Clark Gamblin T, Strong KA, Johnston FM) Fam Cancer 2015 Dec;14(4):641-9 12 Citations |
| 1 | Antioxidant inhibition of steady-state reactive oxygen species and cell growth in neuroblastoma. (Zhu Y, Paul P, Lee S, Craig BT, Rellinger EJ, Qiao J, Gius DR, Chung DH) Surgery 2015 Sep;158(3):827-36 9 Citations |
| 1 | Bromodomain and extraterminal inhibition blocks tumor progression and promotes differentiation in neuroblastoma. (Lee S, Rellinger EJ, Kim KW, Craig BT, Romain CV, Qiao J, Chung DH) Surgery 2015 Sep;158(3):819-26 27 Citations |
| 1 | ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. (Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, Guner G, Munari E, Partin AW, Pavlovich CP, Han M, Carter HB, Bivalacqua TJ, Blackford A, Holt D, Dannals RF, Netto GJ, Lodge MA, Mease RC, Pomper MG, Cho SY) J Nucl Med 2015 Jul;56(7):1003-1010 171 Citations |
| 1 | Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. (Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R) Oncotarget 2015 May 20;6(14):12809-21 81 Citations |
| 1 | CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma. (Sibin MK, Bhat DI, Narasingarao KV, Lavanya Ch, Chetan GK) Tumour Biol 2015 Sep;36(10):7607-14 17 Citations |
| 1 | On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients. (Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R) Mol Cancer Ther 2015 Jun;14(6):1488-94 78 Citations |
| 1 | Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. (Wen Y, Han J, Chen J, Dong J, Xia Y, Liu J, Jiang Y, Dai J, Lu J, Jin G, Han J, Wei Q, Shen H, Sun B, Hu Z) Int J Cancer 2015 Oct 01;137(7):1679-90 188 Citations |
| 1 | Molecular landscape of pancreatic cancer: implications for current clinical trials. (Heestand GM, Kurzrock R) Oncotarget 2015 Mar 10;6(7):4553-61 86 Citations |
| 1 | Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors. (Shi C, Gonzalez RS, Zhao Z, Koyama T, Cornish TC, Hande KR, Walker R, Sandler M, Berlin J, Liu EH) Am J Clin Pathol 2015 Mar;143(3):398-404 64 Citations |
| 1 | SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. (Gonzalez-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F) J Natl Cancer Inst 2015 Mar;107(3) 31 Citations |
| 1 | Cyclin alterations in diverse cancers: Outcome and co-amplification network. (Schwaederlé M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R) Oncotarget 2015 Feb 20;6(5):3033-42 33 Citations |
| 1 | Androgen receptors beyond prostate cancer: an old marker as a new target. (Munoz J, Wheler JJ, Kurzrock R) Oncotarget 2015 Jan 20;6(2):592-603 34 Citations |
| 1 | MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis. (Cuiffo BG, Campagne A, Bell GW, Lembo A, Orso F, Lien EC, Bhasin MK, Raimo M, Hanson SE, Marusyk A, El-Ashry D, Hematti P, Polyak K, Mechta-Grigoriou F, Mariani O, Volinia S, Vincent-Salomon A, Taverna D, Karnoub AE) Cell Stem Cell 2014 Dec 04;15(6):762-74 153 Citations |
| 1 | Glycomic analysis of membrane glycoproteins with bisecting glycosylation from ovarian cancer tissues reveals novel structures and functions. (Allam H, Aoki K, Benigno BB, McDonald JF, Mackintosh SG, Tiemeyer M, Abbott KL) J Proteome Res 2015 Jan 02;14(1):434-46 43 Citations |
| 1 | Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. (Randall JM, Millard F, Kurzrock R) Cancer Metastasis Rev 2014 Dec;33(4):1109-24 76 Citations |
| 1 | Novel approaches in anaplastic thyroid cancer therapy. (Hsu KT, Yu XM, Audhya AW, Jaume JC, Lloyd RV, Miyamoto S, Prolla TA, Chen H) Oncologist 2014 Nov;19(11):1148-55 47 Citations |
| 1 | Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. (Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, Tan W, Nandy D, Bevan GH, Longenbach S, Sun Z, Lu Y, Wang T, Thibodeau SN, Boardman L, Kohli M, Wang L) Eur Urol 2015 Jan;67(1):33-41 562 Citations |
| 1 | A quest for miRNA bio-marker: a track back approach from gingivo buccal cancer to two different types of precancers. (De Sarkar N, Roy R, Mitra JK, Ghose S, Chakraborty A, Paul RR, Mukhopadhyay I, Roy B) PLoS One 2014;9(8):e104839 31 Citations |
| 1 | Giant cell tumor of soft tissue. (Bresler SC, Wanat KA, Elenitsas R) Cutis 2014 Jun;93(6):278;286-8 1 Citation |
| 1 | Post-GWAS gene-environment interplay in breast cancer: results from the Breast and Prostate Cancer Cohort Consortium and a meta-analysis on 79,000 women. (Barrdahl M, Canzian F, Joshi AD, Travis RC, Chang-Claude J, Auer PL, Gapstur SM, Gaudet M, Diver WR, Henderson BE, Haiman CA, Schumacher FR, Le Marchand L, Berg CD, Chanock SJ, Hoover RN, Rudolph A, Ziegler RG, Giles GG, Baglietto L, Severi G, Hankinson SE, Lindström S, Willet W, Hunter DJ, Buring JE, Lee IM, Zhang S, Dossus L, Cox DG, Khaw KT, Lund E, Naccarati A, Peeters PH, Quirós JR, Riboli E, Sund M, Trichopoulos D, Prentice RL, Kraft P, Kaaks R, Campa D) Hum Mol Genet 2014 Oct 01;23(19):5260-70 34 Citations |
| 1 | Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. (Zhu AX, Borger DR, Kim Y, Cosgrove D, Ejaz A, Alexandrescu S, Groeschl RT, Deshpande V, Lindberg JM, Ferrone C, Sempoux C, Yau T, Poon R, Popescu I, Bauer TW, Gamblin TC, Gigot JF, Anders RA, Pawlik TM) Ann Surg Oncol 2014 Nov;21(12):3827-34 132 Citations |
| 1 | Expressions of ABCG2, CD133, and podoplanin in salivary adenoid cystic carcinoma. (Li W, Tamamura R, Wang B, Liu Q, Liu H, Liu T, Katase N, Xiao J, Nagatsuka H) Biomed Res Int 2014;2014:132349 11 Citations |
| 6 | Comprehensive characterization of glioblastoma tumor tissues for biomarker identification using mass spectrometry-based label-free quantitative proteomics. (Heroux MS, Chesnik MA, Halligan BD, Al-Gizawiy M, Connelly JM, Mueller WM, Rand SD, Cochran EJ, LaViolette PS, Malkin MG, Schmainda KM, Mirza SP) Physiol Genomics 2014 Jul 01;46(13):467-81 39 Citations |
| 1 | HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study. (Gorlick S, Barkauskas DA, Krailo M, Piperdi S, Sowers R, Gill J, Geller D, Randall RL, Janeway K, Schwartz C, Grier H, Meyers PA, Gorlick R, Bernstein M, Marina N) Pediatr Blood Cancer 2014 Sep;61(9):1558-64 20 Citations |
| 1 | CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. (Colbert LE, Petrova AV, Fisher SB, Pantazides BG, Madden MZ, Hardy CW, Warren MD, Pan Y, Nagaraju GP, Liu EA, Saka B, Hall WA, Shelton JW, Gandhi K, Pauly R, Kowalski J, Kooby DA, El-Rayes BF, Staley CA 3rd, Adsay NV, Curran WJ Jr, Landry JC, Maithel SK, Yu DS) Cancer Res 2014 May 15;74(10):2677-87 34 Citations |
| 2 | Hypermethylation of miR-203 in endometrial carcinomas. (Huang YW, Kuo CT, Chen JH, Goodfellow PJ, Huang TH, Rader JS, Uyar DS) Gynecol Oncol 2014 May;133(2):340-5 50 Citations |
| 1 | Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth. (Carter YM, Kunnimalaiyaan S, Chen H, Gamblin TC, Kunnimalaiyaan M) Cancer Biol Ther 2014 May;15(5):510-5 37 Citations |
| 1 | A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. (Hong DS, Gordon MS, Samlowski WE, Kurzrock R, Tannir N, Friedland D, Mendelson DS, Vogelzang NJ, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Appleman LJ) Clin Genitourin Cancer 2014 Jun;12(3):167-177.e2 23 Citations |
| 1 | Intraepithelial sebaceous carcinoma: a case report of an unusual occurrence. (Currie GP, Plaza JA, Harris GJ) Am J Dermatopathol 2014 Aug;36(8):673-6 14 Citations |
| 1 | Sperm associated antigen 9 plays an important role in bladder transitional cell carcinoma. (Kanojia D, Garg M, Saini S, Agarwal S, Parashar D, Jagadish N, Seth A, Bhatnagar A, Gupta A, Kumar R, Lohiya NK, Suri A) PLoS One 2013;8(12):e81348 35 Citations |
| 1 | Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer. (Hall WA, Petrova AV, Colbert LE, Hardy CW, Fisher SB, Saka B, Shelton JW, Warren MD, Pantazides BG, Gandhi K, Kowalski J, Kooby DA, El-Rayes BF, Staley CA 3rd, Volkan Adsay N, Curran WJ, Landry JC, Maithel SK, Yu DS) Oncogene 2014 Nov 20;33(47):5450-6 18 Citations |
| 1 | Expression of NgBR is highly associated with estrogen receptor alpha and survivin in breast cancer. (Wang B, Zhao B, North P, Kong A, Huang J, Miao QR) PLoS One 2013;8(11):e78083 40 Citations |
| 1 | Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: a children's oncology group study. (Borinstein SC, Barkauskas DA, Bernstein M, Goorin A, Gorlick R, Krailo M, Schwartz CL, Wexler LH, Toretsky JA) Pediatr Blood Cancer 2014 Apr;61(4):749-52 10 Citations |
| 1 | Review of estrogen receptor, progesterone receptor, and HER-2/neu immunohistochemistry impacts on treatment for a small subset of breast cancer patients transferring care to another institution. (Jorns JM, Healy P, Zhao L) Arch Pathol Lab Med 2013 Nov;137(11):1660-3 14 Citations |
| 1 | The association between C-reactive protein (CRP) level and biochemical failure-free survival in patients after radiation therapy for nonmetastatic adenocarcinoma of the prostate. (Hall WA, Nickleach DC, Master VA, Prabhu RS, Rossi PJ, Godette K, Cooper S, Jani AB) Cancer 2013 Sep 15;119(18):3272-9 34 Citations |
| 1 | Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma. (Colbert LE, Fisher SB, Hardy CW, Hall WA, Saka B, Shelton JW, Petrova AV, Warren MD, Pantazides BG, Gandhi K, Kowalski J, Kooby DA, El-Rayes BF, Staley CA 3rd, Adsay NV, Curran WJ Jr, Landry JC, Maithel SK, Yu DS) Cancer 2013 Sep 01;119(17):3148-55 106 Citations |
| 1 | Urine vascular biomarkers in Sturge-Weber syndrome. (Sreenivasan AK, Bachur CD, Lanier KE, Curatolo AS, Connors SM, Moses MA, Comi AM) Vasc Med 2013 Jun;18(3):122-8 11 Citations |
| 1 | Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. (Kurzrock R, Atkins J, Wheler J, Fu S, Naing A, Busaidy N, Hong D, Sherman S) Ann Oncol 2013 Sep;24(9):2256-61 30 Citations |
| 1 | A physical sciences network characterization of non-tumorigenic and metastatic cells. (Physical Sciences - Oncology Centers Network, Agus DB, Alexander JF, Arap W, Ashili S, Aslan JE, Austin RH, Backman V, Bethel KJ, Bonneau R, Chen WC, Chen-Tanyolac C, Choi NC, Curley SA, Dallas M, Damania D, Davies PC, Decuzzi P, Dickinson L, Estevez-Salmeron L, Estrella V, Ferrari M, Fischbach C, Foo J, Fraley SI, Frantz C, Fuhrmann A, Gascard P, Gatenby RA, Geng Y, Gerecht S, Gillies RJ, Godin B, Grady WM, Greenfield A, Hemphill C, Hempstead BL, Hielscher A, Hillis WD, Holland EC, Ibrahim-Hashim A, Jacks T, Johnson RH, Joo A, Katz JE, Kelbauskas L, Kesselman C, King MR, Konstantopoulos K, Kraning-Rush CM, Kuhn P, Kung K, Kwee B, Lakins JN, Lambert G, Liao D, Licht JD, Liphardt JT, Liu L, Lloyd MC, Lyubimova A, Mallick P, Marko J, McCarty OJ, Meldrum DR, Michor F, Mumenthaler SM, Nandakumar V, O'Halloran TV, Oh S, Pasqualini R, Paszek MJ, Philips KG, Poultney CS, Rana K, Reinhart-King CA, Ros R, Semenza GL, Senechal P, Shuler ML, Srinivasan S, Staunton JR, Stypula Y, Subramanian H, Tlsty TD, Tormoen GW, Tseng Y, van Oudenaarden A, Verbridge SS, Wan JC, Weaver VM, Widom J, Will C, Wirtz D, Wojtkowiak J, Wu PH) Sci Rep 2013;3:1449 136 Citations |
| 1 | Consensus guidelines for the management and treatment of neuroendocrine tumors. (Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC, North American Neuroendocrine Tumor Society) Pancreas 2013 May;42(4):557-77 487 Citations |
| 1 | Fool's gold, lost treasures, and the randomized clinical trial. (Stewart DJ, Kurzrock R) BMC Cancer 2013 Apr 16;13:193 48 Citations |
| 1 | Expression and humoral response of A-kinase anchor protein 4 in cervical cancer. (Agarwal S, Saini S, Parashar D, Verma A, Jagadish N, Batra A, Suri S, Bhatnagar A, Gupta A, Ansari AS, Lohiya NK, Suri A) Int J Gynecol Cancer 2013 May;23(4):650-8 22 Citations |
| 1 | LGALS3BP regulates centriole biogenesis and centrosome hypertrophy in cancer cells. (Fogeron ML, Müller H, Schade S, Dreher F, Lehmann V, Kühnel A, Scholz AK, Kashofer K, Zerck A, Fauler B, Lurz R, Herwig R, Zatloukal K, Lehrach H, Gobom J, Nordhoff E, Lange BM) Nat Commun 2013;4:1531 59 Citations |
| 1 | Multiply recurrent solitary fibrous tumor of the orbit without malignant degeneration: a 45-year clinicopathologic case study. (Griepentrog GJ, Harris GJ, Zambrano EV) JAMA Ophthalmol 2013 Feb;131(2):265-7 15 Citations |
| 1 | Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. (Janku F, Wheler JJ, Hong DS, Kurzrock R) Target Oncol 2013 Sep;8(3):183-188 6 Citations |
| 1 | Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. (Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M) Biol Blood Marrow Transplant 2013 Jul;19(7):1006-12 72 Citations |
| 2 | Mapping MHC haplotype effects in unrelated donor hematopoietic cell transplantation. (Petersdorf EW, Malkki M, Horowitz MM, Spellman SR, Haagenson MD, Wang T) Blood 2013 Mar 07;121(10):1896-905 53 Citations |
| 1 | PDCD4/miR-21 dysregulation in inflammatory bowel disease-associated carcinogenesis. (Ludwig K, Fassan M, Mescoli C, Pizzi M, Balistreri M, Albertoni L, Pucciarelli S, Scarpa M, Sturniolo GC, Angriman I, Rugge M) Virchows Arch 2013 Jan;462(1):57-63 57 Citations |
| 1 | Cancer omics: from regulatory networks to clinical outcomes. (Tang B, Hsu PY, Huang TH, Jin VX) Cancer Lett 2013 Nov 01;340(2):277-83 9 Citations |
| 1 | RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. (Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, Schultz CJ, Choucair A, Dolled-Filhart M, Christiansen J, Gustavson M, Molinaro A, Mischel P, Dicker AP, Bredel M, Mehta M) Int J Radiat Oncol Biol Phys 2013 Apr 01;85(5):1206-11 130 Citations |
| 1 | Occult tumour cells in peritoneal lavage are a negative prognostic factor in pancreatic cancer. (Havlik R, Srovnal J, Klos D, Benedikova A, Lovecek M, Ghothim M, Cahova D, Neoral C, Hajduch M) Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013 Sep;157(3):233-8 7 Citations |
| 5 | Effect of prophylactic central compartment neck dissection on serum thyroglobulin and recommendations for adjuvant radioactive iodine in patients with differentiated thyroid cancer. (Wang TS, Evans DB, Fareau GG, Carroll T, Yen TW) Ann Surg Oncol 2012 Dec;19(13):4217-22 65 Citations |
| 1 | Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. (Kim Y, Ignatchenko V, Yao CQ, Kalatskaya I, Nyalwidhe JO, Lance RS, Gramolini AO, Troyer DA, Stein LD, Boutros PC, Medin JA, Semmes OJ, Drake RR, Kislinger T) Mol Cell Proteomics 2012 Dec;11(12):1870-84 80 Citations |
| 1 | CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. (Anderson MW, Zhao S, Freud AG, Czerwinski DK, Kohrt H, Alizadeh AA, Houot R, Azambuja D, Biasoli I, Morais JC, Spector N, Molina-Kirsch HF, Warnke RA, Levy R, Natkunam Y) Am J Pathol 2012 Sep;181(3):795-803 47 Citations |
| 1 | Primary clear cell carcinoid tumors of the vulva. (Srivastava SA, Wang Y, Vallone J, Felix JC) Am J Surg Pathol 2012 Sep;36(9):1371-5 7 Citations |
| 1 | The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival. (Bommert KS, Effenberger M, Leich E, Küspert M, Murphy D, Langer C, Moll R, Janz S, Mottok A, Weissbach S, Rosenwald A, Bargou R, Bommert K) Leukemia 2013 Feb;27(2):441-50 45 Citations |
| 1 | Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. (Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, Aaberg TM Jr, Altaweel MM, Bardenstein DS, Finger PT, Gallie BL, Harocopos GJ, Hovland PG, McGowan HD, Milman T, Mruthyunjaya P, Simpson ER, Smith ME, Wilson DJ, Wirostko WJ, Harbour JW) Ophthalmology 2012 Aug;119(8):1596-603 416 Citations |
| 1 | PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. (Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K, Dong M, Phan AT, Wolff RA, Gupta S, Mills GB, Yao J) Clin Cancer Res 2012 Mar 15;18(6):1777-89 191 Citations |
| 1 | Correlation of a priori DCE-MRI and (1)H-MRS data with molecular markers in neck nodal metastases: Initial analysis. (Jansen JF, Carlson DL, Lu Y, Stambuk HE, Moreira AL, Singh B, Patel SG, Kraus DH, Wong RJ, Shaha AR, Shah JP, Shukla-Dave A) Oral Oncol 2012 Aug;48(8):717-22 55 Citations |
| 3 | Immunophenotypic stability of Sézary cells by flow cytometry: usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy. (Vaughan J, Harrington AM, Hari PN, Kroft SH, Olteanu H) Am J Clin Pathol 2012 Mar;137(3):403-11 23 Citations |
| 1 | Gamma heavy-chain disease: defining the spectrum of associated lymphoproliferative disorders through analysis of 13 cases. (Bieliauskas S, Tubbs RR, Bacon CM, Eshoa C, Foucar K, Gibson SE, Kroft SH, Sohani AR, Swerdlow SH, Cook JR) Am J Surg Pathol 2012 Apr;36(4):534-43 35 Citations |
| 1 | Antiproliferative and antioxidant potential of beta-ionone against benzo(a)pyrene-induced lung carcinogenesis in Swiss albino mice. (Asokkumar S, Naveenkumar C, Raghunandhakumar S, Kamaraj S, Anandakumar P, Jagan S, Devaki T) Mol Cell Biochem 2012 Apr;363(1-2):335-45 51 Citations |
| 1 | Plasma DNA methylation of Wnt antagonists predicts recurrence of esophageal squamous cell carcinoma. (Liu JB, Qiang FL, Dong J, Cai J, Zhou SH, Shi MX, Chen KP, Hu ZB) World J Gastroenterol 2011 Nov 28;17(44):4917-21 52 Citations |
| 1 | Embryonal rhabdomyosarcoma of the uterine cervix: a report of 14 cases and a discussion of its unusual clinicopathological associations. (Dehner LP, Jarzembowski JA, Hill DA) Mod Pathol 2012 Apr;25(4):602-14 129 Citations |
| 1 | Predictors of malignancy in pancreatic head mass: a prospective study. (Sivaraman A, Muthukrishnan A, Boopathy Senguttvan N, Anil Suchak S, Kannan U) Pan Afr Med J 2011;9:30 4 Citations |
| 1 | Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. (Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, Cherfi A, Öberg KE) J Clin Endocrinol Metab 2011 Dec;96(12):3741-9 186 Citations |
| 1 | ChIP-seq defined genome-wide map of TGFβ/SMAD4 targets: implications with clinical outcome of ovarian cancer. (Kennedy BA, Deatherage DE, Gu F, Tang B, Chan MW, Nephew KP, Huang TH, Jin VX) PLoS One 2011;6(7):e22606 30 Citations |
| 2 | Clinicopathologic analysis of the impact of CD23 expression in plasma cell myeloma with t(11;14)(q13;q32). (Buonaccorsi JN, Kroft SH, Harrington AM, VanTuinen P, Olteanu H) Ann Diagn Pathol 2011 Dec;15(6):385-8 6 Citations |
| 1 | Hyaline globules in neuroendocrine and solid-pseudopapillary neoplasms of the pancreas: a clue to the diagnosis. (Meriden Z, Shi C, Edil BH, Ellison T, Wolfgang CL, Cornish TC, Schulick RD, Hruban RH) Am J Surg Pathol 2011 Jul;35(7):981-8 43 Citations |
| 1 | STT3A, C1orf24, TFF3: putative markers for characterization of follicular thyroid neoplasms from fine-needle aspirates. (Patel MR, Stadler ME, Deal AM, Kim HS, Shores CG, Zanation AM) Laryngoscope 2011 May;121(5):983-9 10 Citations |
| 1 | Targeted methylation of two tumor suppressor genes is sufficient to transform mesenchymal stem cells into cancer stem/initiating cells. (Teng IW, Hou PC, Lee KD, Chu PY, Yeh KT, Jin VX, Tseng MJ, Tsai SJ, Chang YS, Wu CS, Sun HS, Tsai KD, Jeng LB, Nephew KP, Huang TH, Hsiao SH, Leu YW) Cancer Res 2011 Jul 01;71(13):4653-63 93 Citations |
| 1 | Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). (Jiang T, Kambadakone A, Kulkarni NM, Zhu AX, Sahani DV) Invest Radiol 2012 Jan;47(1):11-7 140 Citations |
| 2 | The unique immunophenotype of double-hit lymphomas. (Harrington AM, Olteanu H, Kroft SH, Eshoa C) Am J Clin Pathol 2011 Apr;135(4):649-50 34 Citations |
| 1 | Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia. (Bachanova V, Sandhu K, Yohe S, Cao Q, Burke MJ, Verneris MR, Weisdorf D) Blood 2011 May 12;117(19):5261-3 14 Citations |
| 1 | Predictive and prognostic markers in colorectal cancer. (George B, Kopetz S) Curr Oncol Rep 2011 Jun;13(3):206-15 44 Citations |
| 1 | A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. (Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, González-Angulo AM, Mills GB, Miller WR, Wu H, Shyr Y, Arteaga CL) Clin Cancer Res 2011 Apr 01;17(7):2024-34 84 Citations |
| 1 | Potent antitumor and antineoplastic efficacy of baicalein on benzo(a)pyrene-induced experimental pulmonary tumorigenesis. (Naveenkumar C, Asokkumar S, Raghunandhakumar S, Jagan S, Anandakumar P, Augustine TA, Kamaraj S, Devaki T) Fundam Clin Pharmacol 2012 Apr;26(2):259-70 26 Citations |
| 3 | CD200 expression in plasma cell myeloma. (Olteanu H, Harrington AM, Hari P, Kroft SH) Br J Haematol 2011 May;153(3):408-11 36 Citations |
| 3 | CD23 expression in follicular lymphoma: clinicopathologic correlations. (Olteanu H, Fenske TS, Harrington AM, Szabo A, He P, Kroft SH) Am J Clin Pathol 2011 Jan;135(1):46-53 34 Citations |
| 1 | Expression of mucin (MUC) genes in mucoepidermoid carcinoma. (Shemirani N, Osipov V, Kolker A, Khampang P, Kerschner JE) Laryngoscope 2011 Jan;121(1):167-70 14 Citations |
| 1 | CLU blocks HDACI-mediated killing of neuroblastoma. (Subramanian C, Jarzembowski JA, Halsey SM, Kuick R, Opipari AW Jr, Castle VP, Kwok RP) Tumour Biol 2011 Apr;32(2):285-94 3 Citations |
| 1 | Expression of prox1, lymphatic endothelial nuclear transcription factor, in Kaposiform hemangioendothelioma and tufted angioma. (Le Huu AR, Jokinen CH, Rubin BP, Mihm MC, Weiss SW, North PE, Dadras SS) Am J Surg Pathol 2010 Nov;34(11):1563-73 91 Citations |
| 3 | Adamantinoma with plasmacytoid features: expanding the spectrum of a diagnostically challenging entity. (Walters MP, Baynes K, Carrera GF, King DM, Wang D, Charlson J, Zambrano E) Ann Diagn Pathol 2011 Oct;15(5):347-54 2 Citations |
| 1 | Increased expression of macrophage migration inhibitory factor during progression to hypopharyngeal squamous cell carcinoma. (Cludts S, Decaestecker C, Johnson B, Lechien J, Leroy X, Kindt N, Kaltner H, André S, Gabius HJ, Saussez S) Anticancer Res 2010 Sep;30(9):3313-9 16 Citations |
| 1 | Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival. (Dai J, Jin G, Dong J, Chen Y, Xu L, Hu Z, Shen H) J Thorac Oncol 2010 Nov;5(11):1748-54 |
| 1 | Cystic paraganglioma of the anterior mediastinum. (Ortega PF, Sosa LA, Patel M, Zambrano E) Ann Diagn Pathol 2010 Oct;14(5):341-6 6 Citations |
| 1 | High levels of expression of human stromal cell-derived factor-1 are associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. (Liang JJ, Zhu S, Bruggeman R, Zaino RJ, Evans DB, Fleming JB, Gomez HF, Zander DS, Wang H) Cancer Epidemiol Biomarkers Prev 2010 Oct;19(10):2598-604 59 Citations |
| 1 | Tumor antigen analysis in neuroblastoma by serological interrogation of bioinformatic data. (Kohler ME, Johnson BD, Palen K, Chen QR, Khan J, Orentas RJ) Cancer Sci 2010 Nov;101(11):2316-24 6 Citations |
| 1 | A lectin affinity workflow targeting glycosite-specific, cancer-related carbohydrate structures in trypsin-digested human plasma. (Drake PM, Schilling B, Niles RK, Braten M, Johansen E, Liu H, Lerch M, Sorensen DJ, Li B, Allen S, Hall SC, Witkowska HE, Regnier FE, Gibson BW, Fisher SJ) Anal Biochem 2011 Jan 01;408(1):71-85 57 Citations |
| 1 | Clear cell change in colonic tubular adenoma and corresponding colonic clear cell adenocarcinoma is associated with an altered mucin core protein profile. (Shi C, Scudiere JR, Cornish TC, Lam-Himlin D, Park JY, Fox MR, Montgomery EA) Am J Surg Pathol 2010 Sep;34(9):1344-50 11 Citations |
| 1 | Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. (Bardsley MR, Horváth VJ, Asuzu DT, Lorincz A, Redelman D, Hayashi Y, Popko LN, Young DL, Lomberk GA, Urrutia RA, Farrugia G, Rubin BP, Ordog T) Gastroenterology 2010 Sep;139(3):942-52 101 Citations |
| 1 | Tissue microarrays: one size does not fit all. (Eckel-Passow JE, Lohse CM, Sheinin Y, Crispen PL, Krco CJ, Kwon ED) Diagn Pathol 2010 Jul 07;5:48 40 Citations |
| 1 | Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer. (Parker AS, Heckman MG, Sheinin Y, Wu KJ, Hilton TW, Diehl NN, Pisansky TM, Schild SE, Kwon ED, Buskirk SJ) Int J Radiat Oncol Biol Phys 2011 Apr 01;79(5):1343-9 32 Citations |
| 1 | B-cell chronic lymphocytic leukemia risk in association with serum leptin and adiponectin: a case-control study in Greece. (Dalamaga M, Crotty BH, Fargnoli J, Papadavid E, Lekka A, Triantafilli M, Karmaniolas K, Migdalis I, Dionyssiou-Asteriou A, Mantzoros CS) Cancer Causes Control 2010 Sep;21(9):1451-9 22 Citations |
| 1 | Ectopic expression of wild-type FGFR3 cooperates with MYC to accelerate development of B-cell lineage neoplasms. (Zingone A, Cultraro CM, Shin DM, Bean CM, Morse HC 3rd, Janz S, Kuehl WM) Leukemia 2010 Jun;24(6):1171-8 21 Citations |
| 1 | Elevated PIN1 expression by C/EBPalpha-p30 blocks C/EBPalpha-induced granulocytic differentiation through c-Jun in AML. (Pulikkan JA, Dengler V, Peer Zada AA, Kawasaki A, Geletu M, Pasalic Z, Bohlander SK, Ryo A, Tenen DG, Behre G) Leukemia 2010 May;24(5):914-23 47 Citations |
| 1 | In-depth proteomic analyses of direct expressed prostatic secretions. (Drake RR, Elschenbroich S, Lopez-Perez O, Kim Y, Ignatchenko V, Ignatchenko A, Nyalwidhe JO, Basu G, Wilkins CE, Gjurich B, Lance RS, Semmes OJ, Medin JA, Kislinger T) J Proteome Res 2010 May 07;9(5):2109-16 64 Citations |
| 1 | A microRNA expression signature for cervical cancer prognosis. (Hu X, Schwarz JK, Lewis JS Jr, Huettner PC, Rader JS, Deasy JO, Grigsby PW, Wang X) Cancer Res 2010 Feb 15;70(4):1441-8 278 Citations |
| 1 | Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. (Metcalf RA, Zhao S, Anderson MW, Lu ZS, Galperin I, Marinelli RJ, Cherry AM, Lossos IS, Natkunam Y) Mod Pathol 2010 Mar;23(3):420-33 44 Citations |
| 1 | Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia. (Seegmiller AC, Kroft SH, Karandikar NJ, McKenna RW) Am J Clin Pathol 2009 Dec;132(6):940-9 90 Citations |
| 3 | Utility of CD56 immunohistochemical studies in follow-up of plasma cell myeloma. (Harrington AM, Hari P, Kroft SH) Am J Clin Pathol 2009 Jul;132(1):60-6 24 Citations |
| 1 | Genomic alterations in tumor stroma. (Eng C, Leone G, Orloff MS, Ostrowski MC) Cancer Res 2009 Sep 01;69(17):6759-64 45 Citations |
| 2 | Histopathologic and immunophenotypic profile of subglottic hemangioma: multicenter study. (Badi AN, Kerschner JE, North PE, Drolet BA, Messner A, Perkins JA) Int J Pediatr Otorhinolaryngol 2009 Sep;73(9):1187-91 39 Citations |
| 1 | Comprehensive profiling of the cell surface proteome of Sy5Y neuroblastoma cells yields a subset of proteins associated with tumor differentiation. (Garcia J, Faca V, Jarzembowski J, Zhang Q, Park J, Hanash S) J Proteome Res 2009 Aug;8(8):3791-6 21 Citations |
| 1 | Capsaicin alleviates the imbalance in xenobiotic metabolizing enzymes and tumor markers during experimental lung tumorigenesis. (Anandakumar P, Kamaraj S, Jagan S, Ramakrishnan G, Naveenkumar C, Asokkumar S, Devaki T) Mol Cell Biochem 2009 Nov;331(1-2):135-43 33 Citations |
| 1 | Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. (Dong X, Jiao L, Li Y, Evans DB, Wang H, Hess KR, Abbruzzese JL, Li D) J Clin Oncol 2009 Apr 01;27(10):1592-9 45 Citations |
| 1 | Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. (Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, Harari PM) Clin Cancer Res 2009 Mar 01;15(5):1585-92 84 Citations |
| 1 | Primary mesenteric angiosarcoma in a child with associated lymphangiectasia: a case report. (Castro EC, Galambos C, Shaw PH, Ranganathan S) Pediatr Dev Pathol 2008;11(6):482-6 8 Citations |
| 1 | Quantum dot bioconjugates for in vitro diagnostics & in vivo imaging. (Xing Y, Rao J) Cancer Biomark 2008;4(6):307-19 202 Citations |
| 1 | Prevalence and frequency of circulating t(14;18)-MBR translocation carrying cells in healthy individuals. (Schüler F, Dölken L, Hirt C, Kiefer T, Berg T, Fusch G, Weitmann K, Hoffmann W, Fusch C, Janz S, Rabkin CS, Dölken G) Int J Cancer 2009 Feb 15;124(4):958-63 83 Citations |
| 1 | Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. (Liang JJ, Wang H, Rashid A, Tan TH, Hwang RF, Hamilton SR, Abbruzzese JL, Evans DB, Wang H) Clin Cancer Res 2008 Nov 01;14(21):7043-9 93 Citations |
| 3 | Treatment of diffuse large B-cell lymphoma of the liver with yttrium-90 microsphere embolization. (Fenske TS, Benjamin H, Kroft SH, Hohenwalter EJ, Rilling WS) Nat Clin Pract Oncol 2008 Nov;5(11):677-81 1 Citation |
| 1 | Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. (Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, Blute ML, Kwon ED) Clin Cancer Res 2008 Aug 15;14(16):5150-7 236 Citations |
| 1 | Medullary thyroid carcinoma without marked elevation of calcitonin: a diagnostic and surveillance dilemma. (Wang TS, Ocal IT, Sosa JA, Cox H, Roman S) Thyroid 2008 Aug;18(8):889-94 43 Citations |
| 1 | Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. (Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, Isaacs WB, Luo J, De Marzo AM) Mod Pathol 2008 Sep;21(9):1156-67 348 Citations |
| 1 | Differential display identifies overexpression of the USP36 gene, encoding a deubiquitinating enzyme, in ovarian cancer. (Li J, Olson LM, Zhang Z, Li L, Bidder M, Nguyen L, Pfeifer J, Rader JS) Int J Med Sci 2008 Jun 06;5(3):133-42 24 Citations |
| 1 | Comparison of digital image analysis versus visual assessment to assess survivin expression as an independent predictor of survival for patients with clear cell renal cell carcinoma. (Parker AS, Lohse CM, Leibovich BC, Cheville JC, Sheinin YM, Kwon ED) Hum Pathol 2008 Aug;39(8):1176-84 14 Citations |
| 1 | Wagner-Meissner neurilemmoma of the right cheek. (Wu AJ, Jarzembowski J, Morag Y, Lucas DR) Ann Diagn Pathol 2008 Jun;12(3):204-7 4 Citations |
| 1 | Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer. (Okazaki T, Jiao L, Chang P, Evans DB, Abbruzzese JL, Li D) Clin Cancer Res 2008 Apr 01;14(7):2042-8 48 Citations |
| 1 | Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides. (Cen P, Duvic M, Cohen PR, Kurzrock R) J Am Acad Dermatol 2008 Mar;58(3):382-6 5 Citations |
| 1 | Targeted glycoproteomic identification of biomarkers for human breast carcinoma. (Abbott KL, Aoki K, Lim JM, Porterfield M, Johnson R, O'Regan RM, Wells L, Tiemeyer M, Pierce M) J Proteome Res 2008 Apr;7(4):1470-80 88 Citations |
| 1 | External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. (Hoffmann NE, Sheinin Y, Lohse CM, Parker AS, Leibovich BC, Jiang Z, Kwon ED) Cancer 2008 Apr 01;112(7):1471-9 119 Citations |
| 1 | Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer. (Nguyen TT, Wright JD, Powell MA, Gibb RK, Rader JS, Allsworth JE, Mutch DG) Int J Gynecol Cancer 2008;18(6):1194-9 14 Citations |
| 1 | Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. (Leibovich BC, Sheinin Y, Lohse CM, Thompson RH, Cheville JC, Zavada J, Kwon ED) J Clin Oncol 2007 Oct 20;25(30):4757-64 164 Citations |
| 2 | Primary mediastinal embryonal carcinoma masquerading as chronic pancreatitis. (Kaikobad M, Cheng YC, Choi H, Teves D) WMJ 2007 Jul;106(4):225-8 2 Citations |
| 1 | Molecular profiling of single cancer cells and clinical tissue specimens with semiconductor quantum dots. (Xing Y, Smith AM, Agrawal A, Ruan G, Nie S) Int J Nanomedicine 2006;1(4):473-81 48 Citations |
| 1 | Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates. (Gius D, Funk MC, Chuang EY, Feng S, Huettner PC, Nguyen L, Bradbury CM, Mishra M, Gao S, Buttin BM, Cohn DE, Powell MA, Horowitz NS, Whitcomb BP, Rader JS) Cancer Res 2007 Aug 01;67(15):7113-23 79 Citations |
| 1 | Type IV collagen immunostaining is a simple, reliable diagnostic tool for distinguishing between adenomatous and normal pituitary glands. (Jarzembowski J, Lloyd R, McKeever P) Arch Pathol Lab Med 2007 Jun;131(6):931-5 12 Citations |
| 1 | Anaplastic large cell lymphoma: looks can be deceiving. (Jarzembowski JA) Pediatr Dev Pathol 2007;10(3):169-71 |
| 1 | Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. (Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, Evans DB, Vauthey JN, Xie K, Yao JC) Cancer 2007 Apr 15;109(8):1478-86 186 Citations |
| 1 | Tubedown expression correlates with the differentiation status and aggressiveness of neuroblastic tumors. (Martin DT, Gendron RL, Jarzembowski JA, Perry A, Collins MH, Pushpanathan C, Miskiewicz E, Castle VP, Paradis H) Clin Cancer Res 2007 Mar 01;13(5):1480-7 13 Citations |
| 1 | ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. (Reichard KK, McKenna RW, Kroft SH) Mod Pathol 2007 Mar;20(3):310-9 97 Citations |
| 1 | Squamous cell carcinoma arising in a pediatric intra- and paravertebral teratoma. (Jarzembowski JA, Ruiz RE) Pediatr Dev Pathol 2006;9(4):328-31 2 Citations |
| 1 | Emerging use of nanoparticles in diagnosis and treatment of breast cancer. (Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S, O'Regan RM) Lancet Oncol 2006 Aug;7(8):657-67 489 Citations |
| 1 | Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. (Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB, Wolff RA) Ann Surg Oncol 2006 Aug;13(8):1035-46 773 Citations |
| 1 | Gene expression patterns in advanced human cervical cancer. (Grigsby PW, Watson M, Powell MA, Zhang Z, Rader JS) Int J Gynecol Cancer 2006;16(2):562-7 28 Citations |
| 1 | Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing? (Stadler WM, Michaelis LC, Ratain MJ) J Clin Oncol 2005 Nov 01;23(31):8124-5; author reply 8125-6 2 Citations |
| 1 | Tumor-associated alterations in caspase-14 expression in epithelial malignancies. (Krajewska M, Kim H, Shin E, Kennedy S, Duffy MJ, Wong YF, Marr D, Mikolajczyk J, Shabaik A, Meinhold-Heerlein I, Huang X, Banares S, Hedayat H, Reed JC, Krajewski S) Clin Cancer Res 2005 Aug 01;11(15):5462-71 60 Citations |
| 1 | Surgical treatment of non-functioning pancreatic islet cell tumors. (Kouvaraki MA, Solorzano CC, Shapiro SE, Yao JC, Perrier ND, Lee JE, Evans DB) J Surg Oncol 2005 Mar 01;89(3):170-85 62 Citations |
| 1 | Aggressive angiomyxoma of the female genital tract: a clinicopathologic and immunohistochemical study of 12 cases. (Amezcua CA, Begley SJ, Mata N, Felix JC, Ballard CA) Int J Gynecol Cancer 2005;15(1):140-5 61 Citations |
| 1 | Overexpression of synuclein-gamma in pancreatic adenocarcinoma. (Li Z, Sclabas GM, Peng B, Hess KR, Abbruzzese JL, Evans DB, Chiao PJ) Cancer 2004 Jul 01;101(1):58-65 66 Citations |
| 1 | Kaposiform hemangioendothelioma: a study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangioma. (Lyons LL, North PE, Mac-Moune Lai F, Stoler MH, Folpe AL, Weiss SW) Am J Surg Pathol 2004 May;28(5):559-68 330 Citations |
| 1 | Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. (Chang CC, McClintock S, Cleveland RP, Trzpuc T, Vesole DH, Logan B, Kajdacsy-Balla A, Perkins SL) Am J Surg Pathol 2004 Apr;28(4):464-70 233 Citations |
| 1 | A multiplex microsphere bead assay for comparative RNA expression analysis using flow cytometry. (Fuja T, Hou S, Bryant P) J Biotechnol 2004 Mar 18;108(3):193-205 24 Citations |
| 1 | GLUT1 immunoreaction patterns reliably distinguish hemangioblastoma from metastatic renal cell carcinoma. (North PE, Mizeracki A, Mihm MC Jr, Mrak RE) Clin Neuropathol 2000;19(3):131-7 27 Citations |
| 2 | Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals. (Chang CC, Kampalath B, Schultz C, Bunyi-Teopengco E, Logan B, Eshoa C, Dincer AP, Perkins SL) Arch Pathol Lab Med 2003 Feb;127(2):208-12 72 Citations |
| 1 | Oligodendroglioma: pathology and molecular biology. (Engelhard HH, Stelea A, Cochran EJ) Surg Neurol 2002 Aug;58(2):111-7; discussion 117 77 Citations |
| 1 | Comparison of immunophenotypes of small B-cell neoplasms in primary lymph node and concurrent blood or marrow samples. (Xu Y, McKenna RW, Asplund SL, Kroft SH) Am J Clin Pathol 2002 Nov;118(5):758-64 21 Citations |
| 1 | Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. (Chang CC, Lorek J, Sabath DE, Li Y, Chitambar CR, Logan B, Kampalath B, Cleveland RP) Blood 2002 Dec 15;100(13):4671-5 54 Citations |
| 1 | Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. (Sisk EA, Soltys SG, Zhu S, Fisher SG, Carey TE, Bradford CR) Head Neck 2002 Sep;24(9):841-9 102 Citations |
| 1 | Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker. (Powell MA, Mutch DG, Rader JS, Herzog TJ, Huang TH, Goodfellow PJ) Cancer 2002 Jun 01;94(11):2941-52 55 Citations |
| 1 | Immunophenotype does not correlate with lymph node histology in chronic lymphocytic leukemia/small lymphocytic lymphoma. (Asplund SL, McKenna RW, Howard MS, Kroft SH) Am J Surg Pathol 2002 May;26(5):624-9 34 Citations |
| 1 | Are infantile hemangiomas of placental origin? (North PE, Waner M, Brodsky MC) Ophthalmology 2002 Apr;109(4):633-4 45 Citations |
| 4 | PTHrP during petrosal sinus sampling. (Raff H, Shaker JL, Magill SB, Kehoe ME, Findling JW) Clin Endocrinol (Oxf) 2002 Mar;56(3):419 |
| 1 | Are infantile hemangioma of placental origin? (North PE, Waner M, Brodsky MC) Ophthalmology 2002 Feb;109(2):223-4 28 Citations |
| 1 | Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features. (Leonard JR, Cai DX, Rivet DJ, Kaufman BA, Park TS, Levy BK, Perry A) J Neurosurg 2001 Jul;95(1):82-8 90 Citations |
| 1 | [Expression of p21 WAF1/CIP1 protein in colorectal cancers: study of its relation to p53 mutation and Ki67 antigen expression]. (Chapusot C, Assem M, Martin L, Chalabreyssse L, Benhamiche AM, Lignier MA, Chauffert B, Teyssier JR, Faivre J, Piard F) Pathol Biol (Paris) 2001 Mar;49(2):115-23 |
| 1 | p21WAF1 expression is associated with improved survival after adjuvant chemoradiation for pancreatic cancer. (Ahrendt SA, Brown HM, Komorowski RA, Zhu YR, Wilson SD, Erickson BA, Ritch PS, Pitt HA, Demeure MJ) Surgery 2000 Oct;128(4):520-30 30 Citations |
| 1 | A phase I study of recombinant interferon-beta in patients with advanced malignant disease. (Ravandi F, Estrov Z, Kurzrock R, Breitmeyer JB, Maschek BJ, Talpaz M) Clin Cancer Res 1999 Dec;5(12):3990-8 16 Citations |
| 1 | Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. (Bold RJ, Hess KR, Pearson AS, Grau AM, Sinicrope FA, Jennings M, McConkey DJ, Bucana CD, Cleary KR, Hallin PA, Chiao PJ, Abbruzzese JL, Evans DB) J Gastrointest Surg 1999;3(3):263-77 45 Citations |
| 3 | T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. (Drobyski WR, Hessner MJ, Klein JP, Kabler-Babbitt C, Vesole DH, Margolis DA, Keever-Taylor CA) Blood 1999 Jul 15;94(2):434-41 78 Citations |
| 1 | Antinuclear antibodies as potential markers of lung cancer. (Fernández-Madrid F, VandeVord PJ, Yang X, Karvonen RL, Simpson PM, Kraut MJ, Granda JL, Tomkiel JE) Clin Cancer Res 1999 Jun;5(6):1393-400 55 Citations |
| 1 | p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. (Zheng W, Khurana R, Farahmand S, Wang Y, Zhang ZF, Felix JC) Am J Surg Pathol 1998 Dec;22(12):1463-73 88 Citations |
| 1 | Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. (Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R) Blood 1998 Aug 15;92(4):1150-9 299 Citations |
| 1 | Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. (Zheng W, Luo MP, Welt C, Lambert-Messerlian G, Sung CJ, Zhang Z, Ying SY, Schneyer AL, Lauchlan SC, Felix JC) Gynecol Oncol 1998 Apr;69(1):23-31 71 Citations |
| 1 | Bladder cancer screening. (Kryger JV, Messing E) Semin Oncol 1996 Oct;23(5):585-97 25 Citations |
| 1 | Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). (Estrov Z, Talpaz M, Zipf TF, Kantarjian HM, Ku S, Ouspenskaia MV, Hirsch-Ginsberg C, Huh Y, Yee G, Kurzrock R) J Cell Physiol 1996 Mar;166(3):618-30 27 Citations |
| 1 | Pancreatic adenocarcinoma cell line, MDAPanc-28, with features of both acinar and ductal cells. (Frazier ML, Fernández E, de Llorens R, Brown NM, Pathak S, Cleary KR, Abbruzzese JL, Berry K, Olive M, Le Maistre A, Evans DB) Int J Pancreatol 1996 Feb;19(1):31-8 30 Citations |
| 1 | Tumor antigens in astrocytic gliomas. (Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD) Glia 1995 Nov;15(3):244-56 107 Citations |
| 1 | Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. (Cortes JE, Talpaz M, Cabanillas F, Seymour JF, Kurzrock R) Blood 1995 May 01;85(9):2516-20 55 Citations |
| 1 | Urinary bladder cancer: mechanisms of development and progression. (Kroft SH, Oyasu R) Lab Invest 1994 Aug;71(2):158-74 102 Citations |
| 1 | Immunobiology of malignant astrocytomas. (Kurpad SN, Wikstrand CJ, Bigner DD) Semin Oncol 1994 Apr;21(2):149-61 21 Citations |
| 1 | Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. (Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth MS) J Clin Oncol 1994 Mar;12(3):475-82 447 Citations |
